WO2022094139A1 - Peptide inhibitors for the treatment and prevention of coronavirus infections - Google Patents
Peptide inhibitors for the treatment and prevention of coronavirus infections Download PDFInfo
- Publication number
- WO2022094139A1 WO2022094139A1 PCT/US2021/057132 US2021057132W WO2022094139A1 WO 2022094139 A1 WO2022094139 A1 WO 2022094139A1 US 2021057132 W US2021057132 W US 2021057132W WO 2022094139 A1 WO2022094139 A1 WO 2022094139A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- coronavirus
- cov
- peptide
- sars
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 263
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims description 21
- 238000011282 treatment Methods 0.000 title abstract description 33
- 239000003112 inhibitor Substances 0.000 title abstract description 16
- 230000002265 prevention Effects 0.000 title description 13
- 208000015181 infectious disease Diseases 0.000 claims abstract description 97
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 96
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 67
- 241000711573 Coronaviridae Species 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 51
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 42
- 230000002401 inhibitory effect Effects 0.000 claims description 40
- 241000700605 Viruses Species 0.000 claims description 37
- 241000725579 Feline coronavirus Species 0.000 claims description 28
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 28
- 241000482741 Human coronavirus NL63 Species 0.000 claims description 24
- 230000007502 viral entry Effects 0.000 claims description 22
- 244000309467 Human Coronavirus Species 0.000 claims description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- 230000009385 viral infection Effects 0.000 claims description 16
- 241000711443 Bovine coronavirus Species 0.000 claims description 14
- 241000711506 Canine coronavirus Species 0.000 claims description 14
- 241000709691 Enterovirus E Species 0.000 claims description 14
- 241000711475 Feline infectious peritonitis virus Species 0.000 claims description 14
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 14
- 241000711466 Murine hepatitis virus Species 0.000 claims description 14
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 claims description 14
- 241000711493 Porcine respiratory coronavirus Species 0.000 claims description 14
- 241000903330 Rabbit coronavirus Species 0.000 claims description 14
- 241001428933 Rat coronavirus Species 0.000 claims description 14
- 241000711484 Transmissible gastroenteritis virus Species 0.000 claims description 14
- 229910052727 yttrium Inorganic materials 0.000 claims description 12
- 241000700159 Rattus Species 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 9
- 241000008921 Avian coronavirus Species 0.000 claims description 8
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 claims description 8
- 241001109669 Human coronavirus HKU1 Species 0.000 claims description 8
- 241001428935 Human coronavirus OC43 Species 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 102000048657 human ACE2 Human genes 0.000 claims description 8
- 241001461748 Porcine coronavirus HKU15 Species 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 102000018265 Virus Receptors Human genes 0.000 claims description 6
- 108010066342 Virus Receptors Proteins 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 229940052143 bamlanivimab Drugs 0.000 claims description 4
- 229940051183 casirivimab Drugs 0.000 claims description 4
- 229940051243 etesevimab Drugs 0.000 claims description 4
- 229940051184 imdevimab Drugs 0.000 claims description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 241000288906 Primates Species 0.000 claims description 2
- 241000272525 Anas platyrhynchos Species 0.000 claims 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 abstract description 37
- 230000005764 inhibitory process Effects 0.000 abstract description 28
- 230000008685 targeting Effects 0.000 abstract description 4
- 229940024606 amino acid Drugs 0.000 description 70
- 150000001413 amino acids Chemical class 0.000 description 69
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 66
- 235000001014 amino acid Nutrition 0.000 description 66
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 57
- 108010084592 Saporins Proteins 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 49
- 238000009739 binding Methods 0.000 description 47
- 241000315672 SARS coronavirus Species 0.000 description 40
- 101001092930 Homo sapiens Prosaposin Proteins 0.000 description 36
- 230000003993 interaction Effects 0.000 description 33
- -1 isomers Substances 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 29
- 239000003085 diluting agent Substances 0.000 description 28
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 26
- 101001048716 Homo sapiens ETS domain-containing protein Elk-4 Proteins 0.000 description 26
- 102100022483 Sodium channel and clathrin linker 1 Human genes 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 208000025721 COVID-19 Diseases 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000001404 mediated effect Effects 0.000 description 19
- 230000001603 reducing effect Effects 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 230000009467 reduction Effects 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 230000000840 anti-viral effect Effects 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 108060001084 Luciferase Proteins 0.000 description 12
- 239000005089 Luciferase Substances 0.000 description 12
- 101710198474 Spike protein Proteins 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000036515 potency Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 11
- 101150052032 SAP7 gene Proteins 0.000 description 11
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 102100023794 ETS domain-containing protein Elk-3 Human genes 0.000 description 10
- 101001048720 Homo sapiens ETS domain-containing protein Elk-3 Proteins 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 229940096437 Protein S Drugs 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000000069 prophylactic effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001112090 Pseudovirus Species 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 238000000787 affinity precipitation Methods 0.000 description 6
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 229960005190 phenylalanine Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 208000021601 lentivirus infection Diseases 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000494545 Cordyline virus 2 Species 0.000 description 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 101150117794 SAP4 gene Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000011201 multiple comparisons test Methods 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 229940043230 sarcosine Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000000954 titration curve Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTIIDBURLHHYRK-ZETCQYMHSA-N (2S)-2-(pent-1-enylamino)propanoic acid Chemical compound CCCC=CN[C@@H](C)C(O)=O RTIIDBURLHHYRK-ZETCQYMHSA-N 0.000 description 2
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- DPDPQQHHTHKSRN-UHFFFAOYSA-N 4-aminooxane-4-carboxylic acid Chemical compound OC(=O)C1(N)CCOCC1 DPDPQQHHTHKSRN-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 2
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 2
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 206010063080 Postural orthostatic tachycardia syndrome Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101150033179 SAP3 gene Proteins 0.000 description 2
- 101150106968 SAP8 gene Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108050008392 Viral spike glycoproteins Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127090 anticoagulant agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960004396 famciclovir Drugs 0.000 description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960001447 fomivirsen Drugs 0.000 description 2
- XCWFZHPEARLXJI-UHFFFAOYSA-N fomivirsen Chemical compound C1C(N2C3=C(C(NC(N)=N3)=O)N=C2)OC(CO)C1OP(O)(=S)OCC1OC(N(C)C(=O)\N=C(\N)C=C)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(N=C(N)C=C2)=O)CC1OP(O)(=S)OCC(C(C1)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)OC1N1C=C(C)C(=O)NC1=O XCWFZHPEARLXJI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229950010668 letermovir Drugs 0.000 description 2
- FWYSMLBETOMXAG-QHCPKHFHSA-N letermovir Chemical compound COC1=CC=CC(N2CCN(CC2)C=2N([C@@H](CC(O)=O)C3=CC=CC(F)=C3N=2)C=2C(=CC=C(C=2)C(F)(F)F)OC)=C1 FWYSMLBETOMXAG-QHCPKHFHSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011551 log transformation method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000005067 remediation Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000008786 sensory perception of smell Effects 0.000 description 2
- 230000014860 sensory perception of taste Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- IADUEWIQBXOCDZ-UHFFFAOYSA-N (2S)-azetidine-2-carboxylic acid Natural products OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 1
- VEYYWZRYIYDQJM-SSDOTTSWSA-N (2r)-2-acetamido-6-azaniumylhexanoate Chemical compound CC(=O)N[C@@H](C(O)=O)CCCCN VEYYWZRYIYDQJM-SSDOTTSWSA-N 0.000 description 1
- CPUSCHYXEUZMSV-ZETCQYMHSA-N (2s)-2,6-diamino-2-methylhexanoic acid Chemical compound OC(=O)[C@](N)(C)CCCCN CPUSCHYXEUZMSV-ZETCQYMHSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 description 1
- KGNUPTNIPHPWLT-LBPRGKRZSA-N (2s)-2-[(4-phenylphenyl)methylazaniumyl]propanoate Chemical compound C1=CC(C[NH2+][C@@H](C)C([O-])=O)=CC=C1C1=CC=CC=C1 KGNUPTNIPHPWLT-LBPRGKRZSA-N 0.000 description 1
- ZTTWHZHBPDYSQB-LBPRGKRZSA-N (2s)-2-amino-3-(1h-indol-3-yl)-2-methylpropanoic acid Chemical compound C1=CC=C2C(C[C@@](N)(C)C(O)=O)=CNC2=C1 ZTTWHZHBPDYSQB-LBPRGKRZSA-N 0.000 description 1
- ZEWXVRJSLTXWON-JTQLQIEISA-N (2s)-2-amino-3-(2,4-dimethylphenyl)propanoic acid Chemical compound CC1=CC=C(C[C@H](N)C(O)=O)C(C)=C1 ZEWXVRJSLTXWON-JTQLQIEISA-N 0.000 description 1
- IQMAPACPGQFJNG-KRWDZBQOSA-N (2s)-2-amino-3-(2,5,7-tritert-butyl-1h-indol-3-yl)propanoic acid Chemical compound C1=C(C(C)(C)C)C=C2C(C[C@H](N)C(O)=O)=C(C(C)(C)C)NC2=C1C(C)(C)C IQMAPACPGQFJNG-KRWDZBQOSA-N 0.000 description 1
- NRCSJHVDTAAISV-QMMMGPOBSA-N (2s)-2-amino-3-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C(Cl)=C1 NRCSJHVDTAAISV-QMMMGPOBSA-N 0.000 description 1
- QFGMPXZFCIHYIR-QMMMGPOBSA-N (2s)-2-amino-3-(3,5-difluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(F)=CC(F)=C1 QFGMPXZFCIHYIR-QMMMGPOBSA-N 0.000 description 1
- PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 description 1
- OZVAXCWACWDNIQ-QMMMGPOBSA-N (2s)-2-amino-3-(4-carbamoylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C(N)=O)C=C1 OZVAXCWACWDNIQ-QMMMGPOBSA-N 0.000 description 1
- KWIPUXXIFQQMKN-VIFPVBQESA-N (2s)-2-amino-3-(4-cyanophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C#N)C=C1 KWIPUXXIFQQMKN-VIFPVBQESA-N 0.000 description 1
- DQLHSFUMICQIMB-VIFPVBQESA-N (2s)-2-amino-3-(4-methylphenyl)propanoic acid Chemical compound CC1=CC=C(C[C@H](N)C(O)=O)C=C1 DQLHSFUMICQIMB-VIFPVBQESA-N 0.000 description 1
- CRFFPDBJLGAGQL-QMMMGPOBSA-N (2s)-2-amino-3-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C(F)(F)F)C=C1 CRFFPDBJLGAGQL-QMMMGPOBSA-N 0.000 description 1
- SRGOJUDAJKUDAZ-LURJTMIESA-N (2s)-2-amino-3-cyclobutylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1CCC1 SRGOJUDAJKUDAZ-LURJTMIESA-N 0.000 description 1
- DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 1
- LSNDLIKCFHLFKO-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-hydroxy-2,6-dimethylphenyl)propanoate Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](N)C(O)=O LSNDLIKCFHLFKO-JTQLQIEISA-N 0.000 description 1
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 description 1
- AXDLCFOOGCNDST-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-N 0.000 description 1
- IYDYFVUFSPQPPV-PEXOCOHZSA-N (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-4-[[(2s,3r)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2h-pyran-2-yl]oxy]-2-[(2r,3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CNCCO)O2)N)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CCN IYDYFVUFSPQPPV-PEXOCOHZSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- CMUHFUGDYMFHEI-UHFFFAOYSA-N -2-Amino-3-94-aminophenyl)propanoic acid Natural products OC(=O)C(N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- HTTPGMNPPMMMOP-UHFFFAOYSA-N 1-azaniumyl-2,3-dihydroindene-1-carboxylate Chemical compound C1=CC=C2C(N)(C(O)=O)CCC2=C1 HTTPGMNPPMMMOP-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- UHQFXIWMAQOCAN-UHFFFAOYSA-N 2-amino-1,3-dihydroindene-2-carboxylic acid Chemical compound C1=CC=C2CC(N)(C(O)=O)CC2=C1 UHQFXIWMAQOCAN-UHFFFAOYSA-N 0.000 description 1
- MXHKOHWUQAULOV-UHFFFAOYSA-N 2-azaniumyl-4-cyclohexylbutanoate Chemical compound OC(=O)C(N)CCC1CCCCC1 MXHKOHWUQAULOV-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- KPVIXBKIJXZQJX-FCEONZPQSA-N 21904a5386 Chemical compound O([C@H]1[C@@]2(C)[C@@H]3C(=O)CC[C@]3([C@H]([C@H](O)[C@](C)(C=C)C1)C)CC[C@H]2C)C(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O KPVIXBKIJXZQJX-FCEONZPQSA-N 0.000 description 1
- ZCQVVSMJNBNDAQ-UHFFFAOYSA-N 3-(2-aminoethoxy)propanoic acid Chemical compound NCCOCCC(O)=O ZCQVVSMJNBNDAQ-UHFFFAOYSA-N 0.000 description 1
- ZIAOVIPSKUPPQW-UHFFFAOYSA-N 3-chloro-5-[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile Chemical compound N1C(=O)N(C)C(CN2C(C(OC=3C=C(C=C(Cl)C=3)C#N)=C(C=C2)C(F)(F)F)=O)=N1 ZIAOVIPSKUPPQW-UHFFFAOYSA-N 0.000 description 1
- YXDGRBPZVQPESQ-QMMMGPOBSA-N 4-[(2s)-2-amino-2-carboxyethyl]benzoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C(O)=O)C=C1 YXDGRBPZVQPESQ-QMMMGPOBSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- KHABBYNLBYZCKP-UHFFFAOYSA-N 4-aminopiperidin-1-ium-4-carboxylate Chemical compound OC(=O)C1(N)CCNCC1 KHABBYNLBYZCKP-UHFFFAOYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- FICLVQOYKYBXFN-VIFPVBQESA-N 6-chloro-L-tryptophan Chemical compound ClC1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 FICLVQOYKYBXFN-VIFPVBQESA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GNRLUBOJIGSVNT-UHFFFAOYSA-N Aminoethoxyacetic acid Chemical compound NCCOCC(O)=O GNRLUBOJIGSVNT-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- 101150011571 BSL2 gene Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000112287 Bat coronavirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000003737 Bright-Glo Luciferase Assay System Methods 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- UOAXMMISMWRAMK-SNVBAGLBSA-N C(=CCCCCCC)N[C@H](C)C(=O)O Chemical compound C(=CCCCCCC)N[C@H](C)C(=O)O UOAXMMISMWRAMK-SNVBAGLBSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000633708 Homo sapiens Src kinase-associated phosphoprotein 2 Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- GDFAOVXKHJXLEI-UHFFFAOYSA-N L-N-Boc-N-methylalanine Natural products CNC(C)C(O)=O GDFAOVXKHJXLEI-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FMUMEWVNYMUECA-UHFFFAOYSA-N L-homoleucine Natural products CC(C)CCC(N)C(O)=O FMUMEWVNYMUECA-UHFFFAOYSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- VVNCNSJFMMFHPL-GSVOUGTGSA-N L-penicillamine Chemical compound CC(C)(S)[C@H](N)C(O)=O VVNCNSJFMMFHPL-GSVOUGTGSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- ZKZBPNGNEQAJSX-REOHCLBHSA-N L-selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 description 1
- GHSJKUNUIHUPDF-BYPYZUCNSA-N L-thialysine Chemical compound NCCSC[C@H](N)C(O)=O GHSJKUNUIHUPDF-BYPYZUCNSA-N 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 1
- CFRMVEKWKKDNAH-VKHMYHEASA-N N(4)-methyl-L-asparagine Chemical compound CNC(=O)C[C@H](N)C(O)=O CFRMVEKWKKDNAH-VKHMYHEASA-N 0.000 description 1
- PQNASZJZHFPQLE-UHFFFAOYSA-N N(6)-methyllysine Chemical compound CNCCCCC(N)C(O)=O PQNASZJZHFPQLE-UHFFFAOYSA-N 0.000 description 1
- CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 1
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 description 1
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 description 1
- DTERQYGMUDWYAZ-UHFFFAOYSA-N N-acetyl-N-thioacetyl-Lysine Natural products CC(=O)NCCCCC(N)C(O)=O DTERQYGMUDWYAZ-UHFFFAOYSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- KAFHLONDOVSENM-HNNXBMFYSA-N O-Benzyl-L-tyrosine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OCC1=CC=CC=C1 KAFHLONDOVSENM-HNNXBMFYSA-N 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- GEYBMYRBIABFTA-UHFFFAOYSA-N O-methyltyrosine Chemical compound COC1=CC=C(CC(N)C(O)=O)C=C1 GEYBMYRBIABFTA-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 description 1
- 101100536371 Rattus norvegicus Taok3 gene Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 description 1
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- DLGSOJOOYHWROO-WQLSENKSSA-N [(z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 1
- RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- HYOWVAAEQCNGLE-JTQLQIEISA-N alpha-methyl-L-phenylalanine Chemical compound OC(=O)[C@](N)(C)CC1=CC=CC=C1 HYOWVAAEQCNGLE-JTQLQIEISA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003159 atovaquone Drugs 0.000 description 1
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 description 1
- 229940008411 baloxavir marboxil Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960004069 cefditoren Drugs 0.000 description 1
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- DBPPRLRVDVJOCL-FQRUVTKNSA-N cefiderocol Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1(CCNC(=O)C=2C(=C(O)C(O)=CC=2)Cl)CCCC1 DBPPRLRVDVJOCL-FQRUVTKNSA-N 0.000 description 1
- 229950000788 cefiderocol Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229940036735 ceftaroline Drugs 0.000 description 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- HLFSMUUOKPBTSM-ISIOAQNYSA-N chembl1951095 Chemical compound C([C@H]1C[C@H]2[C@@H](C(=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C1C(=O)C1=C2O)O)N(C)C)C1=C(F)C=C2NC(=O)CN1CCCC1 HLFSMUUOKPBTSM-ISIOAQNYSA-N 0.000 description 1
- PQJQFLNBMSCUSH-SBAJWEJLSA-N chembl2364632 Chemical compound O=C1C2=C(O)[C@@](C(C(C(N)=O)=C(O)[C@H]3N(C)C)=O)(O)[C@H]3C[C@@H]2CC2=C1C(O)=CC=C2CN(C)OC PQJQFLNBMSCUSH-SBAJWEJLSA-N 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 cilastatin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 description 1
- 229960002402 cobicistat Drugs 0.000 description 1
- 229940108538 colistimethate Drugs 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009351 contact transmission Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960005449 daclatasvir Drugs 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 229960002488 dalbavancin Drugs 0.000 description 1
- 108700009376 dalbavancin Proteins 0.000 description 1
- 229960002615 dalfopristin Drugs 0.000 description 1
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 description 1
- 108700028430 dalfopristin Proteins 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- FMTDIUIBLCQGJB-SEYHBJAFSA-N demeclocycline Chemical compound C1([C@@H](O)[C@H]2C3)=C(Cl)C=CC(O)=C1C(=O)C2=C(O)[C@@]1(O)[C@@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FMTDIUIBLCQGJB-SEYHBJAFSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002542 dolutegravir Drugs 0.000 description 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 description 1
- 229950003141 doravirine Drugs 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- 229960002030 edoxudine Drugs 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960003586 elvitegravir Drugs 0.000 description 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229950004877 eravacycline Drugs 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960000628 fidaxomicin Drugs 0.000 description 1
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 229940108452 foscavir Drugs 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 229960000374 ibacitabine Drugs 0.000 description 1
- WEVJJMPVVFNAHZ-RRKCRQDMSA-N ibacitabine Chemical compound C1=C(I)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 WEVJJMPVVFNAHZ-RRKCRQDMSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960000476 inosine pranobex Drugs 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 229940028894 interferon type ii Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960004922 isavuconazonium Drugs 0.000 description 1
- RSWOJTICKMKTER-QXLBVTBOSA-N isavuconazonium Chemical compound CNCC(=O)OCC1=CC=CN=C1N(C)C(=O)OC(C)[N+]1=CN(C[C@@](O)([C@@H](C)C=2SC=C(N=2)C=2C=CC(=CC=2)C#N)C=2C(=CC=C(F)C=2)F)N=C1 RSWOJTICKMKTER-QXLBVTBOSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229950010255 lefamulin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- 208000027028 long COVID Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
- 229950006243 loviride Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000696 methanogenic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960003152 metisazone Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005389 moroxydine Drugs 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 229950004150 omadacycline Drugs 0.000 description 1
- JEECQCWWSTZDCK-IQZGDKDPSA-N omadacycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O JEECQCWWSTZDCK-IQZGDKDPSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001607 oritavancin Drugs 0.000 description 1
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 description 1
- 108010006945 oritavancin Proteins 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 230000006919 peptide aggregation Effects 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 150000002994 phenylalanines Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229950010251 plazomicin Drugs 0.000 description 1
- 229960000471 pleconaril Drugs 0.000 description 1
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 108700028429 quinupristin Proteins 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229940040939 repurposed drug Drugs 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 1
- 229960002814 rilpivirine Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- KNUXHTWUIVMBBY-JRJYXWDASA-N rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 1
- 229950006564 rintatolimod Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229950000534 sarecycline Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004076 secnidazole Drugs 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229960002091 simeprevir Drugs 0.000 description 1
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003879 tedizolid Drugs 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- 229960005240 telavancin Drugs 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 description 1
- 229960004946 tenofovir alafenamide Drugs 0.000 description 1
- 229960001355 tenofovir disoproxil Drugs 0.000 description 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 1
- 229940111527 trizivir Drugs 0.000 description 1
- 229960000832 tromantadine Drugs 0.000 description 1
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 150000003667 tyrosine derivatives Chemical class 0.000 description 1
- 229960004626 umifenovir Drugs 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
Definitions
- Coronavirus disease 2019 (COVID-19) is an ongoing pandemic that has posed a serious threat to public health and global economy.
- the causative agent of COVID-19 is a coronavirus, severe acute respiratory coronavirus 2 (SARS-CoV-2), which first emerged towards the end of 2019 in Wuhan City, China.
- SARS-CoV-2 severe acute respiratory coronavirus 2
- the rapid spread of SARS-CoV-2 is attributable to its high reproductive number, community and asymptomatic spread through close contact, and airborne transmission of respiratory' droplets.
- CO VID-19 patients can become critically ill with severe hypoxemia, viral pneumonia, acute respiratory distress syndrome, and gastrointestinal and neurological symptoms.
- Unfortunately, to date there are relatively few approved drugs specifically designed to treat SARS-CoV-2, with the most common treatments being supportive care and repurposed drugs.
- a wide array of diverse approaches are urgently needed to rapidly and effectively advance antiviral therapies.
- the viral Spike glycoprotein which resides on the viral lipid bilayer of all coronaviruses.
- ACE2 angiotensin-converting enzyme 2
- isolated peptides comprising the sequence EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX 1 DKX2X3I IE (SEQ ID NO: 22),
- peptide comprises the sequence EDX1X2YQ, wherein Xi is L, A, I, V, G, or P; and wherein X2 is F, Y, or W.
- peptides of any preceding aspect wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
- peptides wherein the peptide comprises the sequence LX1X2MY; wherein X1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M (such as, for example, peptides consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ NO: 16, or SEQ ID NO: 17).
- isolated peptides wherein the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X 2 is F, Y, or W; and wherein X 3 is N, Q, S, T, C, or M .
- isolated peptides wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
- the disclosed peptides do not include naturally occurring peptides.
- the peptide comprises the sequence EDX 1 X 2 YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; wherein the peptide comprises the sequence LX1X2MY; and wherein the peptide does not comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.; or wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
- composition comprising one or more of the isolated peptides of any preceding aspect. It is understood and herein contemplated that the combination of multiple different peptides in a single composition can have synergistic or additive effects on the ability to inhibit viral entry by a spike protein, inhibit infection, treat an ongoing infection, and/or provide benefits for longer-term sequalae of infection.
- compositions comprising any combination of two or more of the isolated peptides as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and-SEQ ID NO: 19.
- the disclosed compositions are useful in the treatment and prevention of viral infections.
- compositions of any preceding aspect further comprising one or more antiviral agents (such as, for example, Remdesivir and/or an anti-coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof).
- antiviral agents such as, for example, Remdesivir and/or an anti-coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof.
- a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV), porcine hemagglutinating encephalomyelitis virus (HEV), porcine hemagglutinating ence
- compositions and/or peptides can occur for therapeutic intervention or prophylactic uses.
- the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus.
- a viral infection such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV),
- IBV avian coronavirus
- PEDV porcine epidemic diarrhea virus
- compositions and/or peptides can occur for therapeutic intervention or prophylactic uses.
- the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus.
- a viral infection such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalo
- IBV avian coronavirus
- PEDV porcine epidemic diarrhea virus
- PRCV porcine respiratory cor
- DESCRIPTION OF DRAWINGS Figure 1 is a plot illustrating the dose-dependent inhibition of SARS-CoV-2 Spike- pseudotyped lentivirus infection by SAPs. Dose response curves of the indicated SAPs generated by plotting the percent viral inhibition (y-axis) against the log transformation of SAP concentration (mM, x-axis). Each data point represents the average of three independent experiments, performed in duplicate. Error bars represent standard deviations.
- FIGS. 2A-2C illustrate the inhibition of Spike- and VSV-G-pseudotyped lentivirus infection by SAPs. Luciferase-encoding lentiviruses pseudotyped with indicated viral glycoprotein were incubated with 3 mM of indicated SAP or diluent control for 1 h prior to infection of 293T-ACE2 cells. Infection was measured as relative luciferase expression 48 h post-infection. The luciferase signal obtained for the diluent control was set to 100%.
- Graphs indicate percentage of infected cells normalized to the diluent control for lentiviruses pseudotyped with SARS-CoV-2 Spike (Figure 2A), SARS-CoV Spike ( Figure 2B), or VSV-G ( Figure 2C). Bars represent averages from four independent experiments, performed in duplicate, with means from individual experiments shown as circles. Error bars represent standard deviations. Percent infections were compared to the diluent control using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test. * p ⁇ 0.05, ns, not significant Figures 3A-3C show the binding of SAPs to SARS-CoV-2 Spike.
- ANOVA analysis of variance
- FIG. 3A shows a representative SDS-PAGE gels of affinity precipitation of His-S RBD with increasing concentrations of indicated FITC-SAP (lanes 2–6: 0.125, 0.25, 0.5, 1, and 3 mM FITC-SAP). Lane 1 indicates control precipitation of 3 mM FITC-SAP without His-S RBD. FITC-labeled bands were detected at 488 nm fluorescence and His-S RBD was visualized with Coomassie staining.
- Figure 3B is a graphical representation of fluorescence intensities from (A) of indicated FITC-SAP bound to His-S RBD. Each data point represents the average of three independent experiments. Error bars represent standard deviations. Data were fit to the Hill equation to determine the apparent K d of binding.
- Figure 3C shows the calculated binding K d from three independent experiments ⁇ standard deviations.
- Figures 4A-4B show the inhibition of SARS-CoV-2 infection by SAPs. SARS-CoV- 2 was incubated with 3 mM of indicated SAP or diluent control for 1 h prior to infection of 293T-ACE2-GFP cells.
- Figure 4A shows representative flow cytometry plots indicating percent infection.
- Figure 4B is a graph indicating the percentage of infected cells normalized to the diluent control, which was set to 100%. Bars represent averages from two independent experiments, performed in triplicate, with individual data points shown as circles. Error bars represent standard deviations. Percent infections were compared to the diluent control using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test.
- ANOVA analysis of variance
- Figures 5A-5B show the inhibition of HCoV-NL63 infection by SAPs.
- HCoV-NL63 was incubated with 3 mM of indicated SAP or diluent control for 1 h prior to infection of LLC-MK2 cells. Cytopathic effects and virus titers in the supernatants were analyzed at 72 h post-infection.
- Figure 5A shows representative bright field microscope images showing cytopathic effects.
- Figure 5B is a graph indicating virus titers in supernatants from LLC- MK2 cells. Bars represent averages from triplicate infections with individual data points shown as circles. Error bars represent standard deviations.
- Figure 6A-6C show gaphical illustration of SARS-CoV-2 Spike and SAP6 interaction interface.
- Figure 6A is an overall view of SARS-CoV-2 Spike RBD and human ACE2 interaction mode. N-terminal helix of human ACE2 is located at the central interface.
- Figure 6B shows the relative location of SAP6 (light blue) and SAP1 (green and light blue).
- Figure 6C shows the H-bonds interaction network between SAP6 and SARS-CoV-2 Spike RBD.
- FIG. 7 is a plot illustrating the dose-dependent inhibition of SARS-CoV-2 Spike- pseudotyped lentivirus infection for SAP5 and SAP7. Dose response curves of the indicated SAPs generated by plotting the percent viral inhibition (y-axis) against the log transformation of SAP concentration (mM, x-axis). Each data point represents values from a single experimental run.
- FIGS. 8A-8C illustrate the inhibition of Spike- and VSV-G-pseudotyped lentivirus infection by SAP7. Luciferase-encoding lentiviruses pseudotyped with indicated viral glycoprotein were incubated with 3 mM of SAP7 or diluent control for 1 h prior to infection of 293T-ACE2 cells. Infection was measured as relative luciferase expression 48 h post- infection. The luciferase signal obtained for the diluent control was set to 100%.
- Graphs indicate percentage of infected cells normalized to the diluent control for lentiviruses pseudotyped with SARS-CoV-2 Spike ( Figure 8A), SARS-CoV Spike ( Figure 8B), or VSV-G ( Figure 8C). Bars represent values obtained from a single experiment. Error bars represent standard deviations. DETAILED DESCRIPTION Definitions To facilitate understanding of the disclosure set forth herein, a number of terms are defined below. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.
- the use of the terms “a”, “an”, and “the” when used in conjunction with an element may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” Therefore, an element preceded by “a” or “an” does not, without more constraints, preclude the existence of additional identical elements.
- the use of the term “about” applies to all numeric values, whether or not explicitly indicated. This term generally refers to a range of numbers that one of ordinary skill in the art would consider as a reasonable amount of deviation to the recited numeric values (i.e., having the equivalent function or result).
- this term can be construed as including a deviation of ⁇ 10 percent of the given numeric value provided such a deviation does not alter the end function or result of the value. Therefore, a value of about 1% can be construed to be a range from 0.9% to 1.1%. Furthermore, a range may be construed to include the start and the end of the range. For example, a range of 10% to 20% (i.e., range of 10%-20%) can includes 10% and also includes 20%, and includes percentages in between 10% and 20%, unless explicitly stated otherwise herein. It is understood that when combinations, subsets, groups, etc.
- compositions are disclosed (e.g., combinations of components in a composition, or combinations of steps in a method), that while specific reference of each of the various individual and collective combinations and permutations of these elements may not be explicitly disclosed, each is specifically contemplated and described herein.
- a composition is described herein as including a component of type A, a component of type B, a component of type C, or any combination thereof, it is understood that this phrase describes all of the various individual and collective combinations and permutations of these components.
- the composition described by this phrase could include only a component of type A.
- the composition described by this phrase could include only a component of type B.
- the composition described by this phrase could include only a component of type C. In some embodiments, the composition described by this phrase could include a component of type A and a component of type B. In some embodiments, the composition described by this phrase could include a component of type A and a component of type C. In some embodiments, the composition described by this phrase could include a component of type B and a component of type C. In some embodiments, the composition described by this phrase could include a component of type A, a component of type B, and a component of type C. In some embodiments, the composition described by this phrase could include two or more components of type A (e.g., A1 and A2).
- the composition described by this phrase could include two or more components of type B (e.g., B1 and B2). In some embodiments, the composition described by this phrase could include two or more components of type C (e.g., C1 and C2). In some embodiments, the composition described by this phrase could include two or more of a first component (e.g., two or more components of type A (A1 and A2)), optionally one or more of a second component (e.g., optionally one or more components of type B), and optionally one or more of a third component (e.g., optionally one or more components of type C).
- a first component e.g., two or more components of type A (A1 and A2)
- a second component e.g., optionally one or more components of type B
- a third component e.g., optionally one or more components of type C.
- the composition described by this phrase could include two or more of a first component (e.g., two or more components of type B (B1 and B2)), optionally one or more of a second component (e.g., optionally one or more components of type A), and optionally one or more of a third component (e.g., optionally one or more components of type C).
- the composition described by this phrase could include two or more of a first component (e.g., two or more components of type C (C1 and C2)), optionally one or more of a second component (e.g., optionally one or more components of type A), and optionally one or more of a third component (e.g., optionally one or more components of type B).
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. By “about” is meant within 5% of the value, e.g., within 4, 3, 2, or 1% of the value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself.
- the terms “may,” “optionally,” and “may optionally” are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur.
- the statement that a formulation "may include an excipient” is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.
- administering to a subject includes any route of introducing or delivering to a subject an agent.
- Administration can be carried out by any suitable route, including oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation, via an implanted reservoir, parenteral (e.g., subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques), and the like.
- parenteral e.g., subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques
- Constant administration means that the compounds are administered at the same point in time or essentially immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.
- Systemic administration refers to the introducing or delivering to a subject an agent via a route which introduces or delivers the agent to extensive areas of the subject's body (e.g. greater than 50% of the body), for example through entrance into the circulatory or lymph systems.
- local administration refers to the introducing or delivery to a subject an agent via a route which introduces or delivers the agent to the area or area immediately adjacent to the point of administration and does not introduce the agent systemically in a therapeutically significant amount.
- locally administered agents are easily detectable in the local vicinity of the point of administration but are undetectable or detectable at negligible amounts in distal parts of the subject's body.
- Administration includes self-administration and the administration by another.
- the terms “beneficial agent” and “active agent” are used interchangeably herein to refer to a chemical compound or composition that has a beneficial biological effect.
- Beneficial biological effects include both therapeutic effects, i.e., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, i.e., prevention of a disorder or other undesirable physiological condition.
- the terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, isomers, fragments, analogs, and the like.
- a “decrease” can refer to any change that results in a smaller amount of a symptom, disease, composition, condition, or activity.
- a substance is also understood to decrease the genetic output of a gene when the genetic output of the gene product with the substance is less relative to the output of the gene product without the substance. Also, for example, a decrease can be a change in the symptoms of a disorder such that the symptoms are less than previously observed.
- a decrease can be any individual, median, or average decrease in a condition, symptom, activity, composition in a statistically significant amount.
- the decrease can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% decrease so long as the decrease is statistically significant.
- “Inhibit,” “inhibiting,” and “inhibition” mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level.
- the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
- “Inactivate”, “inactivating” and “inactivation” means to decrease or eliminate an activity, response, condition, disease, or other biological parameter due to a chemical (covalent bond formation) between the ligand and a its biological target.
- “reduce” or other forms of the word, such as “reducing” or “reduction,” is meant lowering of an event or characteristic (e.g., viral replication and spread). It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to.
- “reduces viral replication and spread” means reducing the rate of growth of a tumor relative to a standard or a control.
- the terms “treating” or “treatment” of a subject includes the administration of a drug to a subject with the purpose of preventing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of a disease or disorder.
- the terms “treating” and “treatment” can also refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage , and improvement or remediation of damage post-infection resolution.
- treatment includes the alleviation, in part or in whole, of the symptoms of coronavirus infection (e.g., sore throat, blocked and/or runny nose, cough and/or elevated temperature associated with a common cold).
- Such treatment may include eradication, or slowing of population growth, of a microbial agent associated with inflammation.
- prevent or other forms of the word, such as “preventing” or “prevention,” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce.
- something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed.
- the terms “prevent” or “suppress” can refer to a treatment that forestalls or slows the onset of a disease or condition or reduced the severity of the disease or condition.
- a treatment can treat a disease in a subject having symptoms of the disease, it can also prevent or suppress that disease in a subject who has yet to suffer some or all of the symptoms, including symptoms that present post-infection resolution.
- the term “preventing” a disorder or unwanted physiological event in a subject refers specifically to the prevention of the occurrence of symptoms and/or their underlying cause, wherein the subject may or may not exhibit heightened susceptibility to the disorder or event.
- “prevention” includes reduction in risk of coronavirus infection in patients. However, it will be appreciated that such prevention may not be absolute, i.e., it may not prevent all such patients developing a coronavirus infection, or may only partially prevent an infection in a single individual. As such, the terms “prevention” and “prophylaxis” may be used interchangeably.
- effective amount” of a therapeutic agent is meant a nontoxic but sufficient amount of a beneficial agent to provide the desired effect.
- an “effective amount” of a beneficial can also refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.
- An “effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response.
- a “therapeutically effective amount” of a therapeutic agent refers to an amount that is effective to achieve a desired therapeutic result
- a “prophylactically effective amount” of a therapeutic agent refers to an amount that is effective to prevent an unwanted physiological condition.
- Therapeutically effective and prophylactically effective amounts of a given therapeutic agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the subject.
- terapéuticaally effective amount can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect.
- the precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the drug and/or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.
- the terms “patient,” “subject,” and “individual” may be used interchangeably and refer to either a human or a non-human animal.
- peptide refers broadly to a sequence of two or more amino acids joined together by peptide bonds.
- sequence identity refers to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison.
- a “percentage of sequence identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, I) or the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- the identical nucleic acid base e.g., A, T, C, G, I
- the identical amino acid residue e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys
- sequence similarity or sequence identity between sequences can be performed as follows.
- the sequences can be aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
- the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence.
- the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
- the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In some embodiments, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch, (1970, J. Mol. Biol.
- the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using an NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.
- Another exemplary set of parameters includes a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
- the percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller (1989, Cabios, 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- the peptide sequences described herein can be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al., (1990, J. Mol. Biol, 215: 403-10).
- Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997).
- the default parameters of the respective programs e.g., XBLAST and NBLAST
- substitution denotes that one or more amino acids are replaced by another, biologically similar residue. Examples include substitution of amino acid residues with similar characteristics, e.g., small amino acids, acidic amino acids, polar amino acids, basic amino acids, hydrophobic amino acids and aromatic amino acids. See, for example, the table below.
- one or more Met residues are substituted with norleucine (Nle) which is a bioisostere for Met, but which, as opposed to Met, is not readily oxidized.
- Another example of a conservative substitution with a residue normally not found in endogenous, mammalian peptides and proteins is the conservative substitution of Arg or Lys with, for example, ornithine, canavanine, aminoethylcysteine or another basic amino acid.
- one or more cysteines of a peptide analogue of the invention may be substituted with another residue, such as a serine.
- conservative substitutions of amino acids are grouped by physicochemical properties.
- amino acid or “any amino acid” as used here refers to any and all amino acids, including naturally occurring amino acids (e.g., a-amino acids), unnatural amino acids, modified amino acids, and non-natural amino acids. It includes both D- and L-amino acids. Natural amino acids include those found in nature, such as, e.g., the 23 amino acids that, combine into peptide chains to form the building-blocks of a vast array of proteins. These are primarily L stereoisomers, although a few D-amino acids occur in bacterial envelopes and some antibiotics. The 20 “standard,” natural amino acids are listed in the above tables.
- non-standard natural amino acids are pyrrolysine (found in methanogenic organisms and other eukaryotes), selenocysteine (present in many noneukaryotes as well as most eukaryotes), and N-formylmethionine (encoded by the start codon AUG in bacteria, mitochondria and chloroplasts).
- “Unnatural” or “non-natural” amino acids are non-proteinogenic amino acids (i.e., those not naturally encoded or found in the genetic code) that either occur naturally or are chemically synthesized. Over 140 unnatural amino acids are known and thousands of more combinations are possible.
- unnatural amino acids include P-amino acids (P 3 and p 2 ), homo-amino acids, proline and pyruvic acid derivatives, 3-substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear core amino acids, diamino acids, D-amino acids, alpha-methyl amino acids and N-methyl amino acids.
- Unnatural or non-natural amino acids also include modified amino acids.
- “Modified” amino acids include amino acids (e.g., natural amino acids) that have been chemically modified to include a group, groups, or chemical moiety not naturally present on the amino acid.
- amino acids Unless naturally occurring amino acids are referred to by their full name (e.g. alanine, arginine, etc.), they are designated by their conventional three-letter or single-letter abbreviations (e.g. Ala or A for alanine, Arg or R for arginine, etc.). Unless otherwise indicated, three-letter and single-letter abbreviations of amino acids refer to the L-isomeric form of the amino acid in question .
- L-amino acid refers to the ‘17’ isomeric form of a peptide
- D-aniino acid refers to the “D” isomeric form of a peptide (e.g., Dasp, (D)Asp or D-Asp;
- Amino acid residues in the D isomeric form can be substituted for any L-amino acid residue, as long as the desired function is retained by the peptide.
- D- amino acids may be indicated as customary in lower case when referred to using singleletter abbreviations.
- N-methylglycine N-methylglycine
- Alb a-aminoisobutyric acid
- Dab (2,4-diaminobutanoic acid)
- Dapa (2,3-diaminopropanoic acid)
- y-Glu y-glutamic acid
- Gaba y-aminobutanoic acid
- P-Pro pyrrolidine-3-carboxylic acid
- 8Ado 8-amino-3,6-dioxaoctanoic acid
- phPro p-homoproline
- piiPhe p-homophenylalanine
- Bip P,p di phenyl alanine
- Ida Iminodiacetic acid
- sequences disclosed herein are shown proceeding from left to right, with the left end of the sequence being the N-terminus of the peptide and the right end of the sequence being the C-terminus of the peptide.
- sequences disclosed herein are sequences incorporating a “Hy-” moiety at the amino terminus (N-terminus) of the sequence, and either an “—OH” moiety or an “—NH 2 ” moiety at the carboxy terminus (C-terminus) of the sequence.
- a “Hy-” moiety at the N-terminus of the sequence in question indicates a hydrogen atom, corresponding to the presence of a free primary or secondary amino group at the N-terminus, while an “—OH” or an “—NH 2 ” moiety at the C-terminus of the sequence indicates a hydroxy group or an amino group, corresponding to the presence of an amido (CONH 2 ) group at the C-terminus, respectively.
- a C-terminal “—OH” moiety may be substituted for a C-terminal “—NH 2 ” moiety, and vice- versa.
- NH 2 refers to a free amino group present at the amino terminus of a polypeptide.
- OH refers to a free carboxy group present at the carboxy terminus of a peptide.
- Ac refers to Acetyl protection through acylation of the C- or N-terminus of a polypeptide.
- carboxy refers to —CO2H.
- isostere replacement refers to any amino acid or other analog moiety having chemical and/or structural properties similar to a specified amino acid.
- salts or zwitterionic forms of the peptides or compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
- the salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid.
- Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate,
- amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
- acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
- a pharmaceutically acceptable salt may suitably be a salt chosen, e.g., among acid addition salts and basic salts.
- acid addition salts include chloride salts, citrate salts and acetate salts.
- basic salts include salts where the cation is selected among alkali metal cations, such as sodium or potassium ions, alkaline earth metal cations, such as calcium or magnesium ions, as well as substituted ammonium ions, such as ions of the type N(R1)(R2)(R3)(R4)+, where R1, R2, R3 and R4 independently will typically designate hydrogen, optionally substituted C1-6-alkyl or optionally substituted C2-6-alkenyl.
- Examples of relevant C1-6-alkyl groups include methyl, ethyl, 1-propyl and 2-propyl groups.
- Examples of C2-6-alkenyl groups of possible relevance include ethenyl, 1-propenyl and 2-propenyl.
- Other examples of pharmaceutically acceptable salts are described in “Remington's Pharmaceutical Sciences”, 17th edition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., USA, 1985 (and more recent editions thereof), in the “Encyclopaedia of Pharmaceutical Technology”, 3rd edition, James Swarbrick (Ed.), Informa Healthcare USA (Inc.), NY, USA, 2007, and in J. Pharm. Sci. 66: 2 (1977).
- suitable base salts are formed from bases which form non-toxic salts.
- bases include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, and zinc salts.
- Hemisalts of acids and bases may also be formed, e.g., hemisulphate and hemicalcium salts.
- alkyl includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms.
- Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n- pentyl, n-hexyl, and the like, while saturated branched alkyls include, without limitation, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like.
- saturated, cyclic alkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, while unsaturated cyclic alkyls include, without limitation, cyclopentenyl, cyclohexenyl, and the like.
- mammal refers to any mammalian species such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.
- a “therapeutically effective amount” of the peptide inhibitor of the invention is meant to describe a sufficient amount of the peptide inhibitor to treat a. coronavirus infection (e.g., Covid- 19).
- the therapeutically effective amount will achieve a desired benefit/risk ratio applicable to any medical treatment.
- an “analog” of an amino acid e.g., a “Phe analog” or a “Tyr analog” means an analog of the referenced amino acid.
- a variety of amino acid analogs are known and available in the art, including Phe and Tyr analogs.
- an amino acid analog, e.g., a. Phe analog or a Tyr analog comprises one, two, three, four or five substitutions as compared to Phe or Tyr, respectively.
- the substi tutions are present in the side chai ns of the amino acids.
- a Phe analog has the structure Phe(R 2 ), wherein R 2 is a Hy, OH, CEE, CO2H, CONH2, CONH2OCH2CH2NH2, t-Bu, OCH2CH2NH2, phenoxy, OCH3, OAHyl, Br, Cl, F, Ni l :, N3, or guanadino.
- R 2 is CONH2OCH2CH2NH2, OCH3, CONH2, OCH3 or CO2H.
- Phe analogs include, but are not limited to: hPhe, Phe(4- OMe), a-Me-Phe, hPhe(3,4-dimethoxy), Phetd-CONth), Phe(4-phenoxy), Phe(4- guanadino), Phe(4-tBu), Phe(4-CN), Phe(4-Br), Phe(4-OBzl), Phe(4-NH 2 ), BhPhe(4-F), Phe(4-F), Phe(3,5 DiF), Phe(Cl b.CO -H).
- Tyr analogs include, but are not limited to: hTyr, N-Me-Tyr, Tyr(3-tBu), Tyr(4-Nj) and phTyr.
- ACE2 angiotensin-converting enzyme 2 protein
- ACE2 angiotensin-converting enzyme 2 protein
- certain residues of ACE2 served as contact residues for the spike protein and followed the sequence motif EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX 1 DKX 2 X 3 HE (SEQ ID NO: 22).
- peptides comprising the sequence EDX 1 X 2 YQ; wherein X 1 is L, A, I, V, G, or P; and wherein X 2 is F, Y, or W (for example, EDAFYQ EDLFYQ, EDLYYQ, EDAFYQ, EDAYYQ, EDAWYQ, EDIFYQ, EDIYYQ, EDIWYQ, EDLVFYQ, EDVYYQ, EDVWYQ, EDGFYQ, EDGYYQ, EDGWYQ, EDPFYQ, EDPYYQ, OR EDPWYQ), .
- peptides wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
- isolated peptides wherein the peptide comprises the sequence LX1X2MY; wherein X1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M (such as, for example, peptides consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17 as well as, peptides comprising or consisting of LAQMY, LASMY, LATMY, LACMY, LANMY, LAMMY, LIQMY, LISMY, LITMY, LICMY, LINMY, LIMMY, LVQMY, LVSMY, LVTMY, LVCMY, LVNMY, LVMMY, LLQMY, LLSMY, LLTMY, LLCMY, LLNMY, LLMMY, LGQMY, LGSMY, LGTMY, LGCMY, LGNMY, LGMM
- isolated peptides wherein the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M .
- isolated peptides wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
- the disclosed peptides can be between 6 and 30 amino acids in length, between 10 and 30 amino acids in length.
- the isolated peptides are 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,or 30 amino acids long.
- the disclosed peptides do not include naturally occurring peptides. Therefore, disclosed herein are isolated peptides of any preceding aspect, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; wherein the peptide comprises the sequence LX 1 X 2 MY; and wherein the peptide does not comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.; or wherein the peptide comprises the sequence TFX 1 DKX 2 X 3 HE; and wherein the peptide does not comprise SEQ ID NO:
- compositions comprising one or more of the isolated peptides disclosed herein.
- the composition can comprise any 6-30 amino acid long peptides comprising the sequence motif as set forth in EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX 1 DKX 2 X 3 HE (SEQ ID NO: 22).
- the peptide of the composition can consist of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or-SEQ ID NO: 19.
- the combination of multiple differnt peptides in a single composition can have synergistic effect on the ability to inhibit viral entry by a spike protein, inhibit infection, treat an ongoing infection, and/or provide benefits for longer term sequalae of infection.
- compositions comprising any combination of two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, ninetheen or more of the isolated peptides as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and-SEQ ID NO: 19.
- compositions are useful in the treatment and prevention of coronaviral infections.
- any composition disclosed herein further comprising one or more antiviral agents (such as, for example, Remdesivir and/or an anti-coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof).
- antiviral agents such as, for example, Remdesivir and/or an anti-coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof.
- the dislosed peptides and compositions can be useful in the generation of antibody responses to the spike protein.
- the peptides (such as, for example SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and-SEQ ID NO: 19
- compositions disclosed herein comprising said peptides can cause the virus to agglutinate at the viral entry receptor.
- IgA and IgM antibodies can also provide a vehicle for enhanced endogenous T cell responses (including, but not limited to TH1 and TH2 CD4 T cells responses, the generation and/or activation of CD8 effector T cells, and/or the activation of CD8 memory T cells).
- endogenous T cell responses including, but not limited to TH1 and TH2 CD4 T cells responses, the generation and/or activation of CD8 effector T cells, and/or the activation of CD8 memory T cells.
- methods of stimulating and/or enhancing an endogenous immune response in a subject to a coronavirus comprising administereing to the subject one or more of the peptides and/or compositions disclosed herein.
- the stimulated and/or enhanced endogenous immune response is an IgA or IgM response.
- the stimulated and/or enhanced endogenous immune response is a CD4 and/or CD8 T cell response.
- the disclosed peptides and compositions can be useful in pharmaceutical uses, but also propylitic use such as disinfectant, surface cleaner or in livestock building ventilation systems etc.
- disinfectant, surface cleaners, airfilters, and detergents for cleaning humans, livestock, and/or companion animals comprising any of the peptides or compositions disclosed herein.
- Pharmaceutical Compositions When employed as pharmaceuticals, the peptides and compositions provided herein can be administered in the form of pharmaceutical compositions. These compositions can be prepared as described herein or elsewhere, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
- Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal administration), oral, or parenteral.
- the composition can be formulated and administered a nasal spray or mist.
- the composition can be formulated to deliver the peptides and compositions described herein to the nasal passageways of a subject.
- the composition can be formulated to deliver the peptides and compositions described herein to the upper respiratory tract of a subject.
- the composition can be formulated to deliver the peptides and compositions described herein to the lower respiratory tract of a subject.
- Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, (e.g., intrathecal or intraventricular, administration).
- Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
- the compounds provided herein, or a pharmaceutically acceptable salt thereof are suitable for parenteral administration.
- the compounds provided herein are suitable for intravenous administration.
- the compounds provided herein are suitable for oral administration.
- the compounds provided herein are suitable for topical administration.
- Pharmaceutical compositions and formulations for topical administration may include, but are not limited to, transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- the pharmaceutical compositions provided herein are suitable for parenteral administration.
- the pharmaceutical compositions provided herein are suitable for intravenous administration.
- the pharmaceutical compositions provided herein are suitable for oral administration.
- the pharmaceutical compositions provided herein are suitable for topical administration.
- the composition can comprise a nasal spray or mist. In some embodiments, the composition can be a formulation for use in irrigation of nasal passageways.
- pharmaceutical compositions which contain, as the active ingredient, a compound provided herein in combination with one or more pharmaceutically acceptable carriers (e.g. excipients).
- the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
- the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be, for example, in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- excipients include, without limitation, lactose, dextrose, xylitol, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
- the formulations can additionally include, without limitation, lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; flavoring agents, or combinations thereof.
- the active compound can be effective over a wide dosage range and is generally administered in an effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual subject, the severity of the subject’s symptoms, and the like.
- the compositions provided herein can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including, but not limited to, the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present.
- treatment of a subject with a therapeutically effective amount of a compound described herein can include a single treatment or a series of treatments.
- Dosage, toxicity and therapeutic efficacy of the compounds provided herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
- Compounds exhibiting high therapeutic indices are preferred.
- compositions described herein may further contain (or be administered in combination or alternation with) one or more additional active agents.
- additional active agents include agents for the treatment and/or prevention of coronavirus infections such as SARS-CoV-2 infections (e.g., an anti- coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof), other antimicrobial agents (including antibiotics, antiviral agents and anti-fungal agents), anti-inflammatory agents (including steroids and non-steroidal anti-inflammatory agents), anti-coagulant agents, immunomodulatory agents, anticytokine, antiplatelet agents, and antiseptic agents.
- coronavirus infections such as SARS-CoV-2 infections
- an anti- coronavirus monoclonal antibody such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof
- other antimicrobial agents including antibiotics, antiviral agents and anti-fungal agents
- antibiotics include amikacin, amoxicillin, ampicillin, atovaquone, azithromycin, aztreonam, bacitracin, carbenicillin, cefadroxil, cefazolin, cefdinir, cefditoren, cefepime, cefiderocol, cefoperazone, cefotetan, cefoxitin, cefotaxime, cefpodoxime, cefprozil, ceftaroline, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, chloramphenicol, colistimethate, cefuroxime, cephalexin, cephradine, cilastatin, cinoxacin, ciprofloxacin, clarithromycin, clindamycin, dalbavancin, dalfopristin, daptomycin, demeclocycline, dicloxacillin, doripenem,
- antiviral agents include, but are not limited to, abacavir, acyclovir, adefovir, amantadine, amprenavir, atazanavir, balavir, baloxavir marboxil, boceprevir, cidofovir, cobicistat, daclatasvir, darunavir, delavirdine, didanosine, docasanol, dolutegravir, doravirine, ecoliever, edoxudine, efavirenz, elvitegravir, emtricitabine, enfuvirtide, entecavir, etravirine, famciclovir, fomivirsen, fosamprenavir, forscarnet, fosnonet, famciclovir, favipravir, fomivirsen, foscavir, ganciclovir, ibacitabine, idoxuridine, indinavir, in
- anticoagulant agents include, but are not limited to, heparin, warfarin, rivaroxaban, dabigatran, apixaban, edoxaban, enoxaparin, and fondaparinux.
- antiplatelet agents include, but are not limited to, clopidogrel, ticagrelor, prasugrel, dipyridamole, dipyridamole/aspirin, ticlopidine, and eptifibatide.
- antifungal agents include, but are not limited to, voriconazole, itraconazole, posaconazole, fluconazole, ketoconazole, clotrimazole, isavuconazonium, miconazole, caspofungin, anidulafungin, micafungin, griseofulvin, terbinafine, flucytosine, terbinafine, nystatin, and amphotericin b.
- steroidal anti-inflammatory agents include, but are not limited to, hydrocortisone, dexamethasone, prednisolone, prednisone, triamcinolone, methylprednisolone, budesonide, betamethasone, cortisone, and deflazacort.
- non-steroidal anti-inflammatory drugs include ibuprofen, naproxen, ketoprofen, tolmetin, etodolac, fenoprofen, flurbiprofen, diclofenac, piroxicam, indomethacin, sulindax, meloxicam, nabumetone, oxaprozin, mefenamic acid, and diflunisal.
- additional active agents include chloroquine, hydrochloroquine, Vitamin D, and Vitamin C.
- the disclosed peptides can disrupt and otherwise inhibit viral entry into a cell via ACE2.
- a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic
- IBV avian coronavirus
- PEDV porcine epidemic diarrhea virus
- PRCV porcine respiratory coronavirus
- TGEV
- the subject can be administered a therapeutically effective amount of peptides comprising the sequence EDX1X2YQ (SEQ ID NO: 20); LX 1 X 2 MY (SEQ ID NO: 21), and/or TFX 1 DKX 2 X 3 HE (SEQ ID NO: 22).
- peptide for use in the disclosed methods of inhibiting viral entry comprise the sequence EDX1X2YQ; wherein X1 is L, A, I, V, G, or P; and wherein X2 is F, Y, or W.
- the peptide comprises the sequence EDX 1 X 2 YQ; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
- the peptide comprises the sequence LX 1 X 2 MY; wherein X 1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M (such as, for example, peptides consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17).
- the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M .
- the peptide can comprise the sequence TFX 1 DKX 2 X 3 HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
- the methods of inhibiting viral entry do not use a naturally occurring peptide alone, but can comprise the use of multiple naturally occurring peptides in a composition or one or more naturally occurring peptides in combination with an antiviral agent.
- the peptide comprises the sequence EDX1X2YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; wherein the peptide comprises the sequence LX1X2MY; and wherein the peptide does not comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.; or wherein the peptide comprises the sequence TFX 1 DKX 2 X 3 HE; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO
- compositions and/or peptides can occur for therapeutic intervention or prophylactic uses.
- the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus.
- a viral infection such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HE), porcine hemagglutinating encephalomyelitis virus (HE)
- peptide for use in the disclosed methods of treating, inhibiting, reducing, decreasing, and/or preventing a coronaviral infection comprise the sequence EDX1X2YQ; wherein X1 is L, A, I, V, G, or P; and wherein X 2 is F, Y, or W.
- peptide comprises the sequence EDX1X2YQ; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
- the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X 2 is F, Y, or W; and wherein X 3 is N, Q, S, T, C, or M.
- the peptide used in the disvlosed methods can comprise the sequence TFX1DKX2X3HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
- the methods of inhibiting, reducing, decreasing, and/or preventing a coronaviral infection do not use a naturally occurring peptide alone, but can comprise the use of multiple naturally occurring peptides in a composition or one or more naturally occurring peptides in combination with an antiviral agent.
- the peptide comprises the sequence EDX1X2YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; wherein the peptide comprises the sequence LX1X2MY; and wherein the peptide does not comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.; or wherein the peptide comprises the sequence TFX 1 DKX 2 X 3 HE; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
- compositions and/or peptides can occur for therapeutic intervention or prophylactic uses.
- the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus.
- the treatment of the coronaviral infection is not limited to inhibition, reduction, and/or amelioration of the actual infection, but also includes a inhibition, reduction, and/or amelioration of symptoms and long term residual complications and effects resulting from the infection (e.g., post-COVID-syndrome), such symptoms and/or complications including, but not limited to reduced sense of smell and/or taste, memory loss, fatigue, shortness of breath, cough, joint pain, difficulty concentrating, depression, muscle pain, headache, rapid heartbeat, Postural orthostatic tachycardia syndrome, diabetes, and intermittent fever.
- symptoms and/or complications including, but not limited to reduced sense of smell and/or taste, memory loss, fatigue, shortness of breath, cough, joint pain, difficulty concentrating, depression, muscle pain, headache, rapid heartbeat, Postural orthostatic tachycardia syndrome, diabetes, and intermittent fever.
- any of the peptides and/or compositions disclosed herein can be used to prevent, inhibit, reduce, ameliorate, and/or alleviate any one or combination of these symptoms in a subject with an active coronaviral infection as well as after clearance of said infection.
- a coronalviral infection such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCo
- IBV avian coronavirus
- PEDV porcine epidemic diarrhea virus
- PRCV porcine respiratory coronavirus
- TGEV transmissible gastroenteritis virus
- FCoV feline coronavirus
- FIPV feline infectious peritonitis virus
- FECV feline enteric coronavirus
- CoV coronavirus
- RaCoV rabbit coronavirus
- peptide for use in the disclosed methods of treating, inhibiting, reducing, ameliorating, alleviating, and/or preventing one or more symptoms or post-infection complications of a coronaviral infection comprise the sequence EDX1X2YQ; wherein X1 is L, A, I, V, G, or P; and wherein X2 is F, Y, or W.
- peptide comprises the sequence EDX1X2YQ; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
- the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M.
- the peptide used in the disvlosed methods can comprise the sequence TFX 1 DKX 2 X 3 HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
- Example 1 Rationally designed ACE2-derived peptides inhibit SARS-CoV-2.
- SARS-CoV Severe acute respiratory syndrome coronavirus
- COVID- 19 coronavirus disease 2019
- Coronavirus Spike glycoproteins mediate viral entry and fusion with the host cell, and thus, are essential for viral replication.
- SARS-CoV angiotensin-converting enzyme 2
- RBDs receptor binding domains
- ACE2-derived peptides were designed based on the RBD-ACE2 binding interfaces of SARS-CoV-2 and SARS-CoV.
- SARS-CoV-2 and SARS-CoV Spike- pseudotyped viruses subset of peptides were found to inhibit Spike-mediated infection with IC 50 values in the low millimolar range.
- Two peptides were found that bound Spike RBD in affinity precipitation assays and inhibited infection with genuine SARS-CoV-2.
- these peptides inhibited the replication of a common cold causing coronavirus, which also uses ACE2 as its entry receptor.
- Results from the infection experiments and modeling of the peptides with Spike RBD identified a six amino acid (Glu37-Gln42) ACE2 motif that is important for SARS-CoV-2 inhibition.
- SARS-CoV-2 virions display the characteristic club-shaped projections formed by trimers of viral Spike glycoprotein on their surface.
- Spike proteins are essential for viral replication as they mediate viral entry into the host cell.
- the trimeric Spike protein is cleaved into the S1 and S2 subunits. The cleavage event positions the receptor-binding domain (RBD) in the S1 subunits in a receptor-accessible conformation and induces structural changes in the S2 subunits to stabilize its prefusion state.
- RBD receptor-binding domain
- SARS-CoV and SARS-CoV-2 RBDs bind to the peptidase domain of human angiotensin-converting enzyme 2 (ACE2), which serves as the viral entry receptor. Binding of the RBD to ACE2 triggers another cleavage event of the S2 subunit, which results in formation of the six-helix bundle fusion core necessary for viral-host membrane fusion.
- ACE2 human angiotensin-converting enzyme 2
- SARS-CoV and SARS-CoV-2 Spikes bind ACE2 with a nearly identical binding mode – the N-terminal lobe of the ACE2 peptidase domain binds a concave groove on the Spike RBD.
- SARS-CoV and SARS-CoV-2 have conserved interactions at the RBD-ACE2 binding interface. For example, 17/20 contacting amino acid residues in ACE2 have conserved interactions with the two RBDs. Likewise, 13/14 contacting residues in the two RBDs are either conserved or have conservatively substituted side chains.
- SAPs were designed using the following published structures: SARS-CoV-2 Spike S1 subunit bound to ACE2 (PDB codes: 7A91-98), SARS-CoV-2 RBD bound to ACE2 (PDB codes: 6M0J and 6VW1), SARS-CoV RBD bound to ACE2 (PDB code: 2AJF), and SARS-CoV S1-S2 subunits bound to ACE2 (PDB codes: 6ACK, 6ACJ, 6ACC, 6ACD, and 6ACG).
- Recombinant His-tagged SARS-CoV-2 Spike RBD (His-S RBD, amino acids Arg319- Phe541) was purchased from RayBiotech. Affinity precipitation assay. Affinity precipitation assays using Ni-NTA beads (GE Healthcare) were performed with His-S RBD and FITC-SAPs using known methods. Briefly, Ni-NTA beads were equilibrated in binding buffer (50 mM Tris pH 7.5, 250 mM NaCl, 50 mM LPLGD]ROH ⁇ DQG ⁇ P0 ⁇ -mercaptoethanol).
- Binding reactions were setup by incubating equilibrated Ni-NTA beads with His-S RBD (1 ⁇ M) and increasing concentrations (3, 1, 0.5, 0.25, and 0.125 mM) of indicated FITC-SAP in the binding buffer and incubated for 1 h at 4oC.
- control reactions with 3 mM of indicated FITC- SAP without His-S RBD were preformed to rule out non-specific FITC-SAP binding to the Ni-NTA beads. Reactions were spun and washed three times in the binding buffer to remove unbound proteins/peptides.
- the resulting protein-peptide complexes bound to the beads were extracted using NuPAGE lithium dodecyl sulfate sample buffer (Invitrogen), subjected to SDS-PAGE analysis, and visualized by Coomassie staining or fluorescence detection at 488 nm. Resulting FITC-labeled bands were quantified using ImageJ software. To estimate K d values for FITC-SAP binding to His-S RBD, the data were fit to the Hill equation using Origin 8 software (OriginLab). Cells, plasmids, viruses.
- HEK293T ATCC CRL-3216
- HEK293T-ACE2 BEI Resources
- Vero E6 ATCC CRL-1586
- LLC-MK2 LLC-MK2 (ATCC CCL-7) cells were cultured in Dulbecco's modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco).
- DMEM Dulbecco's modified Eagle’s medium
- FBS fetal bovine serum
- HEK293T cells stably expressing GFP-tagged human ACE2 HEK293T-ACE2-GFP were generated using known methods, and were maintained in DMEM supplemented with 10% FBS and 1 ⁇ g/mL puromycin (Sigma).
- Plasmid encoding SARS-CoV-2 Spike was obtained from BEI Resources. Generation of plasmid encoding SARS-CoV Spike (pCAGGS-SARS-CoV Spike) has been described previously. Vesicular stomatitis virus-G (VSV-G) expression plasmid (pMD2.G) was purchased from Addgene. HIV-1-derived luciferase reporter vector (pNL4-3.Luc.R-E-) was obtained from NIH AIDS Reagent Program. SARS-CoV-2 USA-WA1/2020 stock virus was obtained from BEI Resources. Human coronavirus NL63 (HCoV-NL63) stock was obtained from Dr.
- HEK293T cells were transfected with pNL4-3.Luc.Rl? and pCAGGS-SARS-CoV-2 Spike, pCAGGS-SARS- CoV Spike, or pMD2.G using Fugene 6 transfection reagent (Roche) following manufacturer’s protocol. Forty-eight hours post-transfection, virus-containing supernatants were harvested, filtered through 0.45 pm sterile filter, and concentrated using Ami con Ultra-15 centrifugal filters (Millipore).
- HEK293T-ACE2 cells were seeded in pCIear Black 96-well plates (Greiner Bio-One) in 100 pl of DMEM supplemented with 10% FBS at a density of 1.25 x 10 4 cells per well. Sixteen hours after plating, equal amounts (RLUs/ml) of a given pseudovirus were incubated with indicated concentrations of the test peptide or diluent control (IX PBS) in 50 pl of DMEM supplemented with 10% FBS for 1 h at 37°C in a V-bottom 96-well plate. The virus-peptide mixture was then added to the HEK293T- ACE2 cells.
- Polybrene (Sigma) at the final concentration of 5 pg/ml was added to the cells. After 48 h, 100 pl of supernatant was removed from each well and luciferase activity was measured using Bright-Glo Luciferase Assay System (Promega) following the manufacturer’s protocol. Luminescence was detected using an Infinite M PLEX multimode plate reader (Tecan).
- Dose response curves For dose response curves, the pseudovirus inhibition assays were performed with increasing concentrations of SAP (0.001, 0.01, 0.1, 1.0, 2.5, 5.0, and 7.5 mM). Percent viral inhibition was calculated as the percent reduction in luciferase activity of pseudovirus incubated with a given concentration of SAP compared to the pseudovirus incubated with the diluent control. The concentration of SAP that resulted in 50% inhibition of viral replication (ICso) was interpolated from a non-linear, best-fit curve using GraphPad Prism 8.0.2 software.
- Biosafety procedures for live SARS-CoV-2 experiments were performed at Biosafety Level 3 (BSL3) according to the standard operating procedures approved by The Ohio State University BSL3 Operations Group (BOG) and Institutional Biosafety Committee. Infected cells were removed from the BSL3 facility for subsequent analyses after fixation with 4% paraformaldehyde for a minimum of 1 h in accordance with a validated decontamination protocol approved by the BOG and Institutional Biosafety Officer.
- SARS-CoV-2 propagation SARS-CoV-2 USA-WA1/2020 stock was diluted 1 : 10,000 in DMEM and added to confluent Veto E6 cells. After infection for 1 h at 37°C, media was replaced with DMEM supplemented with 4% FBS. Following incubation at 37°C for 72 h, virus-containing supernatant was clarified at 1,000 x g for 10 min to remove cell debris, aliquoted, flash frozen in liquid nitrogen, and stored at -80°C. The viral stock titer was determined by plaque assay on Vero E6 cells in 12-well plates with 0.3% low- melting agarose (Sigma) overlay and visualization with 0.25% crystal violet (Sigma).
- SARS-CoV-2 infections 10 6 plaque-forming units of SARS-CoV -2 were incubated with 3 mM final concentration of the test peptide or diluent control (I X PBS) in 400 pl of DMEM for 1 h at 37°C. The virus-peptide mixture was then added to near-confluent HEK293T-ACE2-GFP cells in a 12-well plate.
- HCoV-NL63 propagation HCoV-NL63 stock was expanded and titered on LLC- MK2 cells using previously described methods. The virus was aliquoted and stored at - 80°C.
- HCoV-NL63 infections HCoV ⁇ NL63 equivalent to MOI of 0.5 was incubated with 3 mM final concentration of the test peptide or diluent control (IX PBS) in 300 pl of DMEM for 1 h at 37°C.
- Confluent LLC-MK2 cells in 6-well plates were washed once with DMEM.
- the virus-peptide mixture was then added to LLC-MK2 cells in triplicate. Infection was allowed to proceed for 1 h at 37°C at which point media was removed and replaced with 1 ml of DMEM: supplemented with 2% FBS. After 72 h, the cytopathic effects (CPE) in each well were imaged under a light microscope.
- CPE cytopathic effects
- HCoV ⁇ NL63 plaque assay Confluent LLC-MK2 cells in 6-well plates were infected with serial dilutions (ranging from 10' 1 to IO" 7 ) of HCoV-NL63 in DMEM. After infection for 1 h at 37°C, cells were washed three times with DMEM and overlaid with 1% low-melting agarose in 2 ml of DMEM supplemented with 2% FBS. After incubation at 37°C for 5 days, cells ⁇ vere fixed with 4% paraformaldehyde for 2 h and plaques were visualized after staining with 0.05% crystal violet.
- Rational design of ACE2-derived peptides In order to design a panel of small peptide-based inhibitors that can block the interaction of SARS-CoV-2 Spike with the ACE2 receptor, a combination of structural and biochemical data, and known amino acid interactions necessary for binding of SARS-CoV and SARS-CoV-2 Spike proteins to ACE2 were utilized.
- the al helix of ACE2 which is cradled in a concave groove formed by the p5 and p6 sheets of the RBD, provides the most contacts with the two RBDs (ACE2 residues Gln24, Thr27, Phe28, Lys31, His34, Glu37, Asp38, Tyr41, and Gln42).
- Additional contacts from ACE2 are provided by a.3 helix (ACE2 residues Leu79, Met82, Tyr83 for the two RBDs), a short loop between alO and al 1 helices (ACE2 residues Gln325 and Glu329 for SARS-CoV RBD and Asn330 for both RBDs), p ⁇ hairpin flanking al 1 helix (ACE2 residue Lys353 for both RBDs), and al 1 helix (ACE2 residues Gly354, Asp355, and Arg357 for both RBDs).
- SAPs were designed using the following criteria: 1) they contain at least three residues predicted to interact with RBDs based on structural data (Table 1, highlighted in bold); 2) they are not highly disordered or unresolved in the crystal structures (such as ACE2 residues 1-18); and 3) the length is more than six and less than 30 amino acids, making them amenable for synthesis.
- Table 1 Spike-targeting ACE2-derived peptides (SAPs) used in Example 1. Amino acid sequence with the residue number of the first and last amino acid in the sequence is indicated. The EDLFYQ motif is underlined. The SARS-CoV and SARS-CoV-2 contacting residues are indicated with bold font.
- SAPs inhibit SARS-CoV-2 Spike-pseudotyped lentivirus infection.
- Lentiviral cores pseudotyped with viral surface glycoproteins offer an alternative to highly pathogenic viruses that require biosafety level 3 (BSL3) or BSL4 facilities.
- pseudotyped viruses can be utilized at BSL2 and are ideal for studies pertaining to viral entry and screening of therapeutic agents that target viral entry, such as the peptides in this study.
- Luciferase-encoding lentiviruses pseudotyped with SARS-CoV-2 Spike were incubated with test peptides to allow binding to the vector particle-associated Spike prior to infection of HEK293T-ACE2 cells. Luciferase production was measured 48 hours post-infection. A titration curve for each peptide was generated for determining its inhibitory concentration (IC50). Of the six SAPs tested, SAP1, SAP2, and SAP6 inhibited SARS-CoV-2 Spike-mediated virus infection with an IC 50 value of 2.39 ⁇ 0.20, 3.72 ⁇ 0.37, and 1.90 ⁇ 0.14 mM, respectively ( Figure 1).
- SAPs that inhibit SARS-CoV-2 Spike- mediated virus infection are also able to inhibit infection mediated by SARS-CoV Spike.
- SAPs with positive inhibitory profiles from Figure 1 were evaluated for their ability to inhibit infection of SARS-CoV Spike- and SARS-CoV-2 Spike-pseudotyped viruses at 3 mM dose, which is within the IC50 range for the test peptides ( Figure 1).
- antiviral activity of SAPs was also measured against lentiviruses pseudotyped with vesicular stomatitis virus Glycoprotein (VSV-G), which utilizes low- density lipoprotein receptor, LDL-R for viral entry.
- VSV-G vesicular stomatitis virus Glycoprotein
- SAP1, SAP2, and SAP6 treatment resulted in ⁇ 1.6–3.5-fold reduction in SARS-CoV-2 Spike-mediated infection ( Figure 2A) and ⁇ 1.9–7.5-fold reduction in SARS-CoV Spike- mediated infection ( Figure 2B). Consistent with the results in Figure 1, SAP5 treatment had no significant effect on SARS-CoV-2 Spike-mediated infection, but resulted in ⁇ 1.5-fold reduction in SARS-CoV Spike-mediated infection. None of the SAPs affected VSV-G- mediated virus infection demonstrating their specificity for inhibiting Spike-mediated viral entry (Figure 2C).
- K d 10.7 ⁇ 4.2 mM
- SAP1, SAP5, and SAP6 were evaluated for their ability to inhibit infection of SARS-CoV-2.
- Viruses was incubated with 3 mM of test peptide or diluent control to allow binding to the virion-associated Spike prior to infection of HEK293T-ACE2-GFP cells. Percent infection was measured by intracellular staining of SARS-CoV-2 N protein and flow cytometry 24 hours post-infection.
- SAP1 and SAP6 In comparison to the diluent control, SAP1 and SAP6 treatment resulted in ⁇ 2-fold reduction in SARS-CoV-2 infection ( Figure 4 A and B). In contrast, SAP5, which does not bind RBD and does not inhibit SARS-CoV-2 Spike- pseudotyped lentiviruses, had no significant effect on virus infection.
- SAP1 and SAP6 Based on the findings that SAP1 and SAP6 have comparable IC 50 values ( Figure 1), bind RBD with similar affinity (Figure 3C), and inhibit SARS-CoV-2 infection to similar levels ( Figure 4B), we conclude that SAP6 contains the minimal necessary residues for inhibition of SARS-CoV-2. SAP1 and SAP6 inhibit HCoV-NL63 infection.
- HCoV-229E In addition to the three highly pathogenic coronaviruses known to infect humans, four low pathogenicity coronaviruses (HCoV-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63) are endemic in humans and cause common cold and upper and lower respiratory tract infections. Of the four endemic human coronaviruses, only HCoV-NL63 uses ACE2 as entry receptor. Similar to SARS- CoV and SARS-CoV-2, the S1 subunit of HCoV-NL63 Spike binds ACE2 to mediate viral entry. Thus, we sought to determine whether SAP1 and SAP6, which inhibit SARS-CoV-2 infection, could also inhibit HCoV-NL63 infection.
- Viruses were incubated with 3 mM of test peptide or diluent control to allow binding to the virion-associated Spike prior to infection of LLC-MK2 cells.
- Virus-induced cytopathic effects (CPEs) and virus titers in the supernatants were measured 72 hours post-infection. Severe CPEs were observed in cells that were infected with viruses treated with diluent control or SAP5 indicating robust viral infection ( Figure 5A). In contrast, reduced CPEs were observed in cells infected with SAP1- or SAP6-treated viruses indicating reduced viral infection.
- SAP6 contains the minimal conserved short EDLFYQ motif present in SAP1 and SAP2, we conclude that it is the minimal essential motif important for inhibition of SARS-CoV-2.
- the co-crystal structure of SARS-CoV-2 Spike RBD and human ACE2 has been recently solved and available through the Protein Data Bank (PDB).
- PDB Protein Data Bank
- magenta surface and ribbon represent the Spike RBD and yellow ribbon corresponds to ACE2.
- the RBD-ACE2 interaction interface is contacted mainly by the N-terminal helix (residues Ile21-Asn51) of ACE2.
- luciferase-encoding lentiviruses pseudotyped with SARS-CoV-2 Spike were incubated with increasing concentrations of SAP7 to allow binding to the vector particle-associated Spike prior to infection of HEK293T-ACE2 cells. Luciferase production was then measured 48 hours post-infection. A titration curve for SAP7 was then generated to determining its inhibitory concentration (IC50). The results are shown Figure 7. As shown in Figure 7, SAP7 inhibited SARS-CoV-2 Spike-mediated virus infection with an IC 50 value of 0.5 mM.
- luciferase-encoding lentiviruses pseudotyped with indicated viral glycoprotein were incubated with 3 mM of SAP7 or diluent control for 1 h prior to infection of 293T-ACE2 cells. Infection was measured as relative luciferase expression 48 h post-infection. The luciferase signal obtained for the diluent control was set to 100%. Graphs indicate percentage of infected cells normalized to the diluent control for lentiviruses pseudotyped with SARS-CoV-2 Spike ( Figure 8A), SARS-CoV Spike ( Figure 8B), or VSV-G ( Figure 8C).
- SAP6 which inhibit SARS-CoV-2 infection - demonstrating the feasibility of targeting Spike-ACE2 interaction interface with peptide-based inhibitors to inhibit virus infection.
- SAP6 which contains the minimal conserved EDLFYQ sequence, highlights the importance of the N- terminal al helix of ACE2 for interaction with Spike protein.
- Such approaches could include increased noncovalent interactions between aromatic amino acid residues and the enhancement of peptide a-helicity to increase the stability of the SAPs.
- SAP1-SAP7 were all soluble in IX Phosphate Buffered Saline (PBS). Further, our most active peptide, SAP6 was readily soluble in IX PBS. To improve the solubility of SAP!
- IX PBS was supplemented with 10% and 5% aqueous NEb, respectively.
- supplementation of IX PBS with 5-10% of aqueous NF Is did not result in any spurious effects when these peptides were tested in various assays at a concentration of 3 mM, which is above the IC50 range for both these peptides.
- solubility of synthetic peptides is often an issue and challenge when working with peptide-based inhibitors, our SAPs are particularly attractive for targeting of SARS-CoV-2 due to their solubility.
- w z e propose to employ a number of structure-based rational design approaches focused on improved conformational matching between SAPs and SARS-CoV-2 Spike protein, which will allow for increased binding affinity and potent viral inhibition.
- Such approaches could include increased noncovalent interactions between aromatic amino acid residues and the enhancement of peptide a-helicity to increase the stability of the SAPs.
- SAP6 contains the minimal conserved short EDLFYQ motif present in SAP1 and SAP2, we conclude that it is useful motif for inhibition of SARS-CoV-2.
- the polar residues (Glu37, Asp38, Tyrd l and Gln42) of SAP6 are able to form a network of hydrogen bonds with ThrSOO, Tyr449, AsnSOl , and Tyr505 of SARS-CoV-2 Spike RBD.
- the carboxy groups of Glu37, Asp38, and Gln42 and hydroxyl group of Tyr41 of SA.P6 interface with Spike cavity surrounded by Gln498, Thr500, Tyr449, Asn501, and Tyr505.
- Tyr41 of SAP6 provides limited hydrophobic interactions.
- S-pentenylalanine can be incorporated into SAP6 to from the peptide staple and help stabilize the a helix.
- the length of SAP6 can be extended by two to three amino acids in conjunction with incorporation of R- octenylalanine/S-pentenylalanine --- this will allow a conformation of /, i + 7, which could stabilize a double helical turn.
- linkers such as introduction of giycine(s) or serine(s) resides between peptides
- linkers can be engineered to further increase the antiviral potency of Jinked peptides.
- SAPS Spike RBD-ACE2 interaction interfaces
- SAP6 SAP6 - SAP3 is derived from a3
- SAP4 is derived from al 1
- SAP6 is derived from al helices of ACE2 and thus predicted to target three distinct interaction of Spike RBD with these regions of ACE2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are peptide inhibitors targeting the SARS-CoV-2 spike protein. The peptide inhibitors can be administered to a subject for the inhibition of coronaviral entry and/or inhibtion and/or treatment of a coronaviral infection.
Description
Peptide Inhibitors for the Treatment and Prevention of
Coronavirus Infections
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit of U.S. Provisional Application No. 63/106,689, filed October 28, 2020, which is hereby incorporated herein by reference in its entirety.
BACKGROUND
Coronavirus disease 2019 (COVID-19) is an ongoing pandemic that has posed a serious threat to public health and global economy. The causative agent of COVID-19 is a coronavirus, severe acute respiratory coronavirus 2 (SARS-CoV-2), which first emerged towards the end of 2019 in Wuhan City, China. By March 2020, the World Health Organization declared COVID-19 a pandemic. The rapid spread of SARS-CoV-2 is attributable to its high reproductive number, community and asymptomatic spread through close contact, and airborne transmission of respiratory' droplets. CO VID-19 patients can become critically ill with severe hypoxemia, viral pneumonia, acute respiratory distress syndrome, and gastrointestinal and neurological symptoms. Unfortunately, to date, there are relatively few approved drugs specifically designed to treat SARS-CoV-2, with the most common treatments being supportive care and repurposed drugs. A wide array of diverse approaches are urgently needed to rapidly and effectively advance antiviral therapies.
SUMMARY
Therapeutics that target essential viral proteins are effective at controlling virus replication and spread. Presently, the key viral target for studies looking at possible treatments and vaccine candidates for SARS-CoV-2 is the viral Spike glycoprotein, which resides on the viral lipid bilayer of all coronaviruses. To invade the host cell, the viral Spike protein binds to the host cell’s angiotensin-converting enzyme 2 (ACE2) receptor, followed by cleavage events that allow the viral envelope to fuse with the host cell membrane.
In one aspect disclosed herein are isolated peptides comprising the sequence EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX 1 DKX2X3I IE (SEQ ID NO: 22), In some aspects, peptide comprises the sequence EDX1X2YQ, wherein Xi is L, A, I, V, G, or P; and wherein X2 is F, Y, or W. For example, disclosed herein are
peptides of any preceding aspect, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. Also disclosed herein are peptides, wherein the peptide comprises the sequence LX1X2MY; wherein X1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M (such as, for example, peptides consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ NO: 16, or SEQ ID NO: 17). In ID some aspects, disclosed herein are isolated peptides, wherein the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M .For example, disclosed herein are isolated peptides, wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. In one aspect, the disclosed peptides do not include naturally occurring peptides. Therefore, disclosed herein are isolated peptides of any preceding aspect, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; wherein the peptide comprises the sequence LX1X2MY; and wherein the peptide does not comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.; or wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. It is understood and herein contemplated that the disclosed peptides can be prepared in a composition with a pharmaceutically acceptable excipient. Thus, in one aspect disclosed herein are composition comprising one or more of the isolated peptides of any preceding aspect. It is understood and herein contemplated that the combination of multiple different peptides in a single composition can have synergistic or additive effects on the ability to inhibit viral entry by a spike protein, inhibit infection, treat an ongoing infection, and/or provide benefits for longer-term sequalae of infection. Thus, in one aspect, disclosed herein are compositions comprising any combination of two or more of the isolated peptides as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and-SEQ ID NO: 19.
The disclosed compositions are useful in the treatment and prevention of viral infections. Thus, in one aspect, disclosed herein are compositions of any preceding aspect further comprising one or more antiviral agents (such as, for example, Remdesivir and/or an anti-coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof). In one aspect, disclosed herein are method of inhibiting, reducing, decreasing, and/or preventing viral entry (such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV), turkey bluecomb coronavirus (TCoV), human coronavirus (HCoV)-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) (SARS-CoV), Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV)-2 (SARS-CoV-2) (including, but not limited to the B1.351 variant, B.1.1.7 variant, USA-WA1/2020, or P.1 variant), or middle east respiratory syndrome (MERS) coronavirus (CoV) (MERS-CoV)) in a cell of a subject comprising administering to the subject a therapeutically effective amount of the isolated peptides of any preceding aspect or a therapeutically effective amount the composition of any preceding aspect; wherein the viral entry receptor comprises human angiotensin-converting enzyme 2 (ACE2). It is understood that the administration of the disclosed peptides and/or compositions can occur for therapeutic intervention or prophylactic uses. Thus, in one aspect, the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus. Also disclosed herein are methods of inhibiting, reducing, decreasing, and/or preventing a viral infection (such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus
(MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV), turkey bluecomb coronavirus (TCoV), human coronavirus (HCoV)-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) (SARS-CoV), Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV)-2 (SARS-CoV-2) (including, but not limited to the B1.351 variant, B.1.1.7 variant, USA-WA1/2020, or P.1 variant), or middle east respiratory syndrome (MERS) coronavirus (CoV) (MERS-CoV)) in a subject comprising administering to the subject a therapeutically effective amount of the isolated peptides of any preceding aspect or a therapeutically effective amount the composition of any preceding aspect. It is understood that the administration of the disclosed peptides and/or compositions can occur for therapeutic intervention or prophylactic uses. Thus, in one aspect, the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus. In one aspect, disclosed herein are methods of treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing a viral infection (such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV), turkey bluecomb coronavirus (TCoV), human coronavirus (HCoV)-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) (SARS-CoV), Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV)-2 (SARS-CoV-2) (including, but not limited to the B1.351 variant, B.1.1.7 variant, USA-WA1/2020, or P.1 variant), or middle east respiratory syndrome (MERS) coronavirus (CoV) (MERS-CoV)) in a subject comprising administering to the subject a therapeutically effective amount of the isolated peptides of any preceding aspect or a therapeutically effective amount the composition of any preceding aspect. It is understood that the administration of the disclosed peptides
and/or compositions can occur for therapeutic intervention or prophylactic uses. Thus, in one aspect, the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus. DESCRIPTION OF DRAWINGS Figure 1 is a plot illustrating the dose-dependent inhibition of SARS-CoV-2 Spike- pseudotyped lentivirus infection by SAPs. Dose response curves of the indicated SAPs generated by plotting the percent viral inhibition (y-axis) against the log transformation of SAP concentration (mM, x-axis). Each data point represents the average of three independent experiments, performed in duplicate. Error bars represent standard deviations. The dotted grey line indicates 50% viral inhibition used to determine the IC50 value. Computed IC50 values for the indicated SAPs from three independent experiments ± standard deviations are shown. Figures 2A-2C illustrate the inhibition of Spike- and VSV-G-pseudotyped lentivirus infection by SAPs. Luciferase-encoding lentiviruses pseudotyped with indicated viral glycoprotein were incubated with 3 mM of indicated SAP or diluent control for 1 h prior to infection of 293T-ACE2 cells. Infection was measured as relative luciferase expression 48 h post-infection. The luciferase signal obtained for the diluent control was set to 100%. Graphs indicate percentage of infected cells normalized to the diluent control for lentiviruses pseudotyped with SARS-CoV-2 Spike (Figure 2A), SARS-CoV Spike (Figure 2B), or VSV-G (Figure 2C). Bars represent averages from four independent experiments, performed in duplicate, with means from individual experiments shown as circles. Error bars represent standard deviations. Percent infections were compared to the diluent control using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test. * p < 0.05, ns, not significant Figures 3A-3C show the binding of SAPs to SARS-CoV-2 Spike. Affinity precipitation of His-tagged SARS-CoV-2 Spike RBD (indicated ‘His-S RBD’) with FITC- SAPs. Figure 3A shows a representative SDS-PAGE gels of affinity precipitation of His-S RBD with increasing concentrations of indicated FITC-SAP (lanes 2–6: 0.125, 0.25, 0.5, 1, and 3 mM FITC-SAP). Lane 1 indicates control precipitation of 3 mM FITC-SAP without His-S RBD. FITC-labeled bands were detected at 488 nm fluorescence and His-S RBD was visualized with Coomassie staining. Figure 3B is a graphical representation of fluorescence intensities from (A) of indicated FITC-SAP bound to His-S RBD. Each data point
represents the average of three independent experiments. Error bars represent standard deviations. Data were fit to the Hill equation to determine the apparent Kd of binding. Figure 3C shows the calculated binding Kd from three independent experiments ± standard deviations. Figures 4A-4B show the inhibition of SARS-CoV-2 infection by SAPs. SARS-CoV- 2 was incubated with 3 mM of indicated SAP or diluent control for 1 h prior to infection of 293T-ACE2-GFP cells. Infection was measured by flow cytometry as percentage of cells positive for SARS-CoV-2 nucleocapsid (N) protein 24 h post-infection. Figure 4A shows representative flow cytometry plots indicating percent infection. Figure 4B is a graph indicating the percentage of infected cells normalized to the diluent control, which was set to 100%. Bars represent averages from two independent experiments, performed in triplicate, with individual data points shown as circles. Error bars represent standard deviations. Percent infections were compared to the diluent control using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test. * p < 0.05, ns, not significant Figures 5A-5B show the inhibition of HCoV-NL63 infection by SAPs. HCoV-NL63 was incubated with 3 mM of indicated SAP or diluent control for 1 h prior to infection of LLC-MK2 cells. Cytopathic effects and virus titers in the supernatants were analyzed at 72 h post-infection. Figure 5A shows representative bright field microscope images showing cytopathic effects. Figure 5B is a graph indicating virus titers in supernatants from LLC- MK2 cells. Bars represent averages from triplicate infections with individual data points shown as circles. Error bars represent standard deviations. Virus titers were compared to the diluent control using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test. * p < 0.05, ns, not significant. Figure 6A-6C show gaphical illustration of SARS-CoV-2 Spike and SAP6 interaction interface. Figure 6A is an overall view of SARS-CoV-2 Spike RBD and human ACE2 interaction mode. N-terminal helix of human ACE2 is located at the central interface. Figure 6B shows the relative location of SAP6 (light blue) and SAP1 (green and light blue). Figure 6C shows the H-bonds interaction network between SAP6 and SARS-CoV-2 Spike RBD. The Y41, Q42, D38, and E37 of SAP6 peptide are involved in H-bond interactions with T500, Y449, N501, and Y505 of SARS-CoV-2 Spike RBD. Corresponding crystal structure: PDB Code: 6M0J (http://www.rcsb.org/structure/6M0J).
Figure 7 is a plot illustrating the dose-dependent inhibition of SARS-CoV-2 Spike- pseudotyped lentivirus infection for SAP5 and SAP7. Dose response curves of the indicated SAPs generated by plotting the percent viral inhibition (y-axis) against the log transformation of SAP concentration (mM, x-axis). Each data point represents values from a single experimental run. The dotted line indicates 50% viral inhibition used to determine the IC50 value. Computed IC50 values for the indicated SAPs are also shown. Figures 8A-8C illustrate the inhibition of Spike- and VSV-G-pseudotyped lentivirus infection by SAP7. Luciferase-encoding lentiviruses pseudotyped with indicated viral glycoprotein were incubated with 3 mM of SAP7 or diluent control for 1 h prior to infection of 293T-ACE2 cells. Infection was measured as relative luciferase expression 48 h post- infection. The luciferase signal obtained for the diluent control was set to 100%. Graphs indicate percentage of infected cells normalized to the diluent control for lentiviruses pseudotyped with SARS-CoV-2 Spike (Figure 8A), SARS-CoV Spike (Figure 8B), or VSV-G (Figure 8C). Bars represent values obtained from a single experiment. Error bars represent standard deviations. DETAILED DESCRIPTION Definitions To facilitate understanding of the disclosure set forth herein, a number of terms are defined below. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference. The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of” and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments of the invention and are also disclosed. Other than where noted, all numbers expressing quantities of ingredients, reaction conditions, geometries, dimensions, and so forth used in the specification and claims are to be understood at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, to be construed in light of the number of significant digits and ordinary rounding approaches.
As used in this specification and the following claims, the terms “comprise” (as well as forms, derivatives, or variations thereof, such as “comprising” and “comprises”) and “include” (as well as forms, derivatives, or variations thereof, such as “including” and “includes”) are inclusive (i.e., open-ended) and do not exclude additional elements or steps. For example, the terms "comprise" and/or "comprising," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. Accordingly, these terms are intended to not only cover the recited element(s) or step(s), but may also include other elements or steps not expressly recited. Furthermore, as used herein, the use of the terms “a”, “an”, and “the” when used in conjunction with an element may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” Therefore, an element preceded by “a” or “an” does not, without more constraints, preclude the existence of additional identical elements. The use of the term “about” applies to all numeric values, whether or not explicitly indicated. This term generally refers to a range of numbers that one of ordinary skill in the art would consider as a reasonable amount of deviation to the recited numeric values (i.e., having the equivalent function or result). For example, this term can be construed as including a deviation of ±10 percent of the given numeric value provided such a deviation does not alter the end function or result of the value. Therefore, a value of about 1% can be construed to be a range from 0.9% to 1.1%. Furthermore, a range may be construed to include the start and the end of the range. For example, a range of 10% to 20% (i.e., range of 10%-20%) can includes 10% and also includes 20%, and includes percentages in between 10% and 20%, unless explicitly stated otherwise herein. It is understood that when combinations, subsets, groups, etc. of elements are disclosed (e.g., combinations of components in a composition, or combinations of steps in a method), that while specific reference of each of the various individual and collective combinations and permutations of these elements may not be explicitly disclosed, each is specifically contemplated and described herein. By way of example, if a composition is described herein as including a component of type A, a component of type B, a component of type C, or any combination thereof, it is understood that this phrase describes all of the various individual and collective combinations and
permutations of these components. For example, in some embodiments, the composition described by this phrase could include only a component of type A. In some embodiments, the composition described by this phrase could include only a component of type B. In some embodiments, the composition described by this phrase could include only a component of type C. In some embodiments, the composition described by this phrase could include a component of type A and a component of type B. In some embodiments, the composition described by this phrase could include a component of type A and a component of type C. In some embodiments, the composition described by this phrase could include a component of type B and a component of type C. In some embodiments, the composition described by this phrase could include a component of type A, a component of type B, and a component of type C. In some embodiments, the composition described by this phrase could include two or more components of type A (e.g., A1 and A2). In some embodiments, the composition described by this phrase could include two or more components of type B (e.g., B1 and B2). In some embodiments, the composition described by this phrase could include two or more components of type C (e.g., C1 and C2). In some embodiments, the composition described by this phrase could include two or more of a first component (e.g., two or more components of type A (A1 and A2)), optionally one or more of a second component (e.g., optionally one or more components of type B), and optionally one or more of a third component (e.g., optionally one or more components of type C). In some embodiments, the composition described by this phrase could include two or more of a first component (e.g., two or more components of type B (B1 and B2)), optionally one or more of a second component (e.g., optionally one or more components of type A), and optionally one or more of a third component (e.g., optionally one or more components of type C). In some embodiments, the composition described by this phrase could include two or more of a first component (e.g., two or more components of type C (C1 and C2)), optionally one or more of a second component (e.g., optionally one or more components of type A), and optionally one or more of a third component (e.g., optionally one or more components of type B). Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. By “about” is meant within 5% of the value, e.g., within 4, 3, 2, or 1% of the value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the
particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. As used herein, the terms "may," "optionally," and "may optionally" are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation "may include an excipient" is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient. “Administration" to a subject includes any route of introducing or delivering to a subject an agent. Administration can be carried out by any suitable route, including oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation, via an implanted reservoir, parenteral (e.g., subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques), and the like. "Concurrent administration", "administration in combination", "simultaneous administration" or "administered simultaneously" as used herein, means that the compounds are administered at the same point in time or essentially immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time. "Systemic administration" refers to the introducing or delivering to a subject an agent via a route which introduces or delivers the agent to extensive areas of the subject's body (e.g. greater than 50% of the body), for example through entrance into the circulatory or lymph systems. By contrast, "local administration" refers to the introducing or delivery to a subject an agent via a route which introduces or delivers the agent to the area or area immediately adjacent to the point of administration and does not introduce the agent systemically in a therapeutically significant amount. For example, locally administered agents are easily detectable in the local vicinity of the point of administration but are undetectable or detectable at negligible amounts in
distal parts of the subject's body. Administration includes self-administration and the administration by another. As used here, the terms “beneficial agent” and “active agent” are used interchangeably herein to refer to a chemical compound or composition that has a beneficial biological effect. Beneficial biological effects include both therapeutic effects, i.e., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, i.e., prevention of a disorder or other undesirable physiological condition. The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, isomers, fragments, analogs, and the like. When the terms “beneficial agent” or “active agent” are used, then, or when a particular agent is specifically identified, it is to be understood that the term includes the agent per se as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, conjugates, active metabolites, isomers, fragments, analogs, etc. A "decrease" can refer to any change that results in a smaller amount of a symptom, disease, composition, condition, or activity. A substance is also understood to decrease the genetic output of a gene when the genetic output of the gene product with the substance is less relative to the output of the gene product without the substance. Also, for example, a decrease can be a change in the symptoms of a disorder such that the symptoms are less than previously observed. A decrease can be any individual, median, or average decrease in a condition, symptom, activity, composition in a statistically significant amount. Thus, the decrease can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% decrease so long as the decrease is statistically significant. "Inhibit," "inhibiting," and "inhibition" mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. “Inactivate”, “inactivating” and “inactivation” means to decrease or eliminate an activity, response, condition, disease, or other biological parameter due to a chemical (covalent bond formation) between the ligand and a its biological target.
By “reduce” or other forms of the word, such as “reducing” or “reduction,” is meant lowering of an event or characteristic (e.g., viral replication and spread). It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reduces viral replication and spread” means reducing the rate of growth of a tumor relative to a standard or a control. As used herein, the terms “treating” or “treatment” of a subject includes the administration of a drug to a subject with the purpose of preventing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of a disease or disorder. The terms “treating” and “treatment” can also refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage , and improvement or remediation of damage post-infection resolution. In particular, the term “treatment” includes the alleviation, in part or in whole, of the symptoms of coronavirus infection (e.g., sore throat, blocked and/or runny nose, cough and/or elevated temperature associated with a common cold). Such treatment may include eradication, or slowing of population growth, of a microbial agent associated with inflammation. By “prevent” or other forms of the word, such as “preventing” or “prevention,” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed. For example, the terms “prevent” or “suppress” can refer to a treatment that forestalls or slows the onset of a disease or condition or reduced the severity of the disease or condition. Thus, if a treatment can treat a disease in a subject having symptoms of the disease, it can also prevent or suppress that disease in a subject who has yet to suffer some or all of the symptoms, including symptoms that present post-infection resolution. As used herein, the term “preventing” a disorder or unwanted physiological event in a subject refers specifically
to the prevention of the occurrence of symptoms and/or their underlying cause, wherein the subject may or may not exhibit heightened susceptibility to the disorder or event. In particular embodiments, “prevention” includes reduction in risk of coronavirus infection in patients. However, it will be appreciated that such prevention may not be absolute, i.e., it may not prevent all such patients developing a coronavirus infection, or may only partially prevent an infection in a single individual. As such, the terms “prevention” and “prophylaxis” may be used interchangeably. By the term “effective amount” of a therapeutic agent is meant a nontoxic but sufficient amount of a beneficial agent to provide the desired effect. The amount of beneficial agent that is “effective” will vary from subject to subject, depending on the age and general condition of the subject, the particular beneficial agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount”. However, an appropriate “effective’ amount in any subject case may be determined by one of ordinary skill in the art using routine experimentation. Also, as used herein, and unless specifically stated otherwise, an “effective amount” of a beneficial can also refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts. An “effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. As used herein, a “therapeutically effective amount” of a therapeutic agent refers to an amount that is effective to achieve a desired therapeutic result, and a “prophylactically effective amount” of a therapeutic agent refers to an amount that is effective to prevent an unwanted physiological condition. Therapeutically effective and prophylactically effective amounts of a given therapeutic agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the subject. The term “therapeutically effective amount” can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect. The precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the drug and/or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the
concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art. The terms “patient,” “subject,” and “individual” may be used interchangeably and refer to either a human or a non-human animal. These terms include mammals such as humans, primates, minks, livestock animals (e.g., bovines, porcines, sheep, deer), companion animals (e.g., equine, canines, felines), rodents (e.g., mice, hamsters, guinea pigs, and rats); and avian animals (e.g., chickens, ducks, and turkeys). The term “peptide,” as used herein, refers broadly to a sequence of two or more amino acids joined together by peptide bonds. It should be understood that this term does not connote a specific length of a polymer of amino acids, nor is it intended to imply or distinguish whether the polypeptide is produced using recombinant techniques, chemical or enzymatic synthesis, or is naturally occurring. The recitations “sequence identity”, “percent identity”, “percent homology”, or, for example, comprising a “sequence 50% identical to,” as used herein, refer to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a “percentage of sequence identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, I) or the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. Calculations of sequence similarity or sequence identity between sequences (the terms are used interchangeably herein) can be performed as follows. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences can be aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In certain embodiments, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide
positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In some embodiments, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch, (1970, J. Mol. Biol. 48: 444-453) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using an NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. Another exemplary set of parameters includes a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller (1989, Cabios, 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The peptide sequences described herein can be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al., (1990, J. Mol. Biol, 215: 403-10). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997).
When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. The term “conservative substitution” as used herein denotes that one or more amino acids are replaced by another, biologically similar residue. Examples include substitution of amino acid residues with similar characteristics, e.g., small amino acids, acidic amino acids, polar amino acids, basic amino acids, hydrophobic amino acids and aromatic amino acids. See, for example, the table below. In some embodiments of the invention, one or more Met residues are substituted with norleucine (Nle) which is a bioisostere for Met, but which, as opposed to Met, is not readily oxidized. Another example of a conservative substitution with a residue normally not found in endogenous, mammalian peptides and proteins is the conservative substitution of Arg or Lys with, for example, ornithine, canavanine, aminoethylcysteine or another basic amino acid. In some embodiments, one or more cysteines of a peptide analogue of the invention may be substituted with another residue, such as a serine. For further information concerning phenotypically silent substitutions in peptides and proteins, see, for example, Bowie et. al. Science 247, 1306-1310, 1990. In the scheme below, conservative substitutions of amino acids are grouped by physicochemical properties. I: neutral, hydrophilic, II: acids and amides, III: basic, IV: hydrophobic, V: aromatic, bulky amino acids.
In the scheme below, conservative substitutions of amino acids are grouped by physicochemical properties. VI: neutral or hydrophobic, VII: acidic, VIII: basic, IX: polar, X: aromatic.
The term “amino acid” or “any amino acid” as used here refers to any and all amino acids, including naturally occurring amino acids (e.g., a-amino acids), unnatural amino acids, modified amino acids, and non-natural amino acids. It includes both D- and L-amino acids. Natural amino acids include those found in nature, such as, e.g., the 23 amino acids that, combine into peptide chains to form the building-blocks of a vast array of proteins. These are primarily L stereoisomers, although a few D-amino acids occur in bacterial envelopes and some antibiotics. The 20 “standard,” natural amino acids are listed in the above tables. The “non-standard,” natural amino acids are pyrrolysine (found in methanogenic organisms and other eukaryotes), selenocysteine (present in many noneukaryotes as well as most eukaryotes), and N-formylmethionine (encoded by the start codon AUG in bacteria, mitochondria and chloroplasts). “Unnatural” or “non-natural” amino acids are non-proteinogenic amino acids (i.e., those not naturally encoded or found in the genetic code) that either occur naturally or are chemically synthesized. Over 140 unnatural amino acids are known and thousands of more combinations are possible. Examples of “unnatural” amino acids include P-amino acids (P3 and p2), homo-amino acids, proline and pyruvic acid derivatives, 3-substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear core amino acids, diamino acids, D-amino acids, alpha-methyl amino acids and N-methyl amino acids. Unnatural or non-natural amino acids also include modified amino acids. “Modified” amino acids include amino acids (e.g., natural amino acids) that have been chemically modified to include a group, groups, or chemical moiety not naturally present on the amino acid.
For the most part, the names of naturally occurring and non-naturally occurring aminoacyl residues used herein follow the naming conventions suggested by the IUPAC Commission on the Nomenclature of Organic Chemistry and the IUPAC-IUB Commission on Biochemical Nomenclature as set out in “Nomenclature of a-Amino Acids (Recommendations, 1974)” Biochemistry', 14(2), (1975). To the extent that the names and abbreviations of amino acids and aminoacyl residues employed in this specification and appended claims differ from those suggestions, they will be made clear to the reader. Some abbreviations useful in describing the invention are defined below.
Abbreviations of Non-Natural Amino Acids and Chemical Moieties (for amino acid derivatives, all L unless stated) Abbreviation Definition Ac- Acetyl Hy Hydrogen (Free N-terminal) Dap L-Diaminopropionic acid Dab L-Diaminobutyric acid Orn L-Ornathine Pen L-Penicillamine Sarc Sarcosine Cit L-Citrulline Cav L-Cavanine Phe-(4-Guanidino) 4-Guanidine-L-Phenylalanine N-MeArg N-Methyl-L-Arginine N-MeTrp N-Methyl-L-Tryptophan N-MeGln N-Methyl-L-Glutamine N-MeAla N-Methyl-L-Alanine N-MeLys N-Methyl-Lysine N-MeAsn N-Methyl-L-Asparagine 6-ChloroTrp 6-Chloro-L-Tryptophan 5-HydroxyTrp 5-Hydroxy-L-Tryptophan 1,2,3,4-tetrahydro-norharman L-1,2,3,4-tetrahydro-norharman 2-Nal L-2-Napthylalanine (also referred to as 2-Nap) 1-Nal L-1-Napthylalanine (also referred to as 1-Nap) Phe(4-OMe) 4-Methoxy-L-phenylalanine Abu 2-Aminobutyric acid
Bip L-^^^ƍ-Biphenylalanine ȕ$OD beta-Alanine ȕK7\U beta homo-L-Tyrosine ȕK7US beta homo-L-Trptophan ȕK$OD beta homo-L-Alanine ȕK/HX^ beta homo-L-Leucine ȕK9DO beta homo-L-Valine Aib 2-aminoisobutyric acid Azt L-azetidine-2-carboxylic acid Tic (3S)-1,2,3,4- Tetrahydroisoquinoline-7-hydroxy- 3-carboxylic Acid Phe(4-OMe) 4-methoxy-L-phenylalanine N-Me-Lys N-Methyl-L-Lysine N-Me-Lys(Ac) N-İ-Acetyl-D-lysine CONH2 Carboxamide COOH Acid 3-Pal L-3-Pyridylalanine Phe(4-F) 4-Fluoro-L-Phenylalanine DMT 2,6-DimethylTyrosine Phe(4-OMe) 4-Methoxyphenylalanine hLeu L-homoLeucine hArg L-homoArginine Į-MeLys alpha-methyl-L-Lysine Į-MeOrn alpha-methyl-L-Ornathine Į-MeLeu alpha-methyl-L-Leucine Į-MeTrp alpha-methyl-L-Tryptophan Į-MePhe alpha-methyl-L-Phenylalanine Į-MeTyr alpha-methyl-L-Tyrosine
Į-DiethylGly Į-DiethylGlycine Lys(Ac) N-İ-acetyl-L-Lysine DTT Dithiothreotol Nle L-Norleucine ȕK7US L-ȕ-homoTrypophan ȕK3KH L-ȕ-homophenylalanine ȕK3UR L-ȕ-homoproline Phe(4-CF3) 4-Trifluoromethyl-L-Phenylalanine ȕ-Glu L-ȕ-Glutamic acid ȕK*OX L-ȕ-homog1utamic acid 2-2-Indane 2-Aminoindane-2-carboxylic acid 1-1-Indane 1-Aminoindane-1-carboxylic acid hCha L-homocyclohexylalanine Cyclobutyl L-cyclobutylalanine ȕK3KH L-ȕ-homo-phenylalanine Gla Gama-Carboxy-L-Glutamic acid Cpa Cyclopentyl-L-alanine Cha Cyclohexyl-L-alanine Octgly L-Octylglycine t-butyl-Ala 3-(tert-butyl)-L-Ala-OH t-butyl-Gly tert-butyl-glycine AEP 3-(2-aminoethoxy)propanoic acid AEA (2-aminoethoxy)acetic acid Phe(4-Phenoxy)] 4-Phenoxy-L-phenylalanine Phe(4-OBzl) O-Benzyl-L-tyrosine Phe(4-CONH2) 4-Carbamoyl-L-phenylalanine Phe(4-CO2H) 4-Carboxy-L-phenylalanine Phe(3,4-Cl2) 3,4 dichloro-L-phenylalanine Tyr(3-t-Bu) 3-t-butyl-L-tyrosine
Phe(t-Bu) t-butyl-L-phenylalanine Phe[4-(2-aminoethoxy)]
Phe(4-CN) 4-cyano-L-phenylalanine Phe(4-Br) 4-bromo-L-phenylalanine Phe(4-NH2) 4-amino-L-phenylalanine Phe(4-Me) 4-methyl-L-phenylalanine 4-Pyridylalanine 4-L-Pyridylalanine 4-amino-4-carboxy- piperidine
hPhe(3,4-dimethoxy) 3,4-dimethoxy-L-homophenylalanine Phe(2,4-Me2) 2,4-dimethyl-L-phenylalanine Phe(3,5-F2) 3,5-difluoro-L-phenylalanine Phe(penta-F) pentafluoro-L-phenylalanine 2,5,7-tert butyl Trp 2,5,7-Tris-tert-butyl-L-tryptophan
Tic Phe(4-OAlly1) Phe(4-N3) Achc Acvc Acbc
Acpc
1- aminocyclopropylcarboxylic acid
4-amino-4- carboxy- tetrahydropyran
Throughout the present specification, unless naturally occurring amino acids are referred to by their full name (e.g. alanine, arginine, etc.), they are designated by their conventional three-letter or single-letter abbreviations (e.g. Ala or A for alanine, Arg or R for arginine, etc.). Unless otherwise indicated, three-letter and single-letter abbreviations of amino acids refer to the L-isomeric form of the amino acid in question . The term “L-amino acid,” as used herein, refers to the ‘17’ isomeric form of a peptide, and conversely the term “D-aniino acid” refers to the “D” isomeric form of a peptide (e.g., Dasp, (D)Asp or D-Asp;
Dphe, (D)Phe or D-Phe). Amino acid residues in the D isomeric form can be substituted for any L-amino acid residue, as long as the desired function is retained by the peptide. D- amino acids may be indicated as customary in lower case when referred to using singleletter abbreviations.
In the case of less common or non-naturally occurring amino acids, unless they are referred to by their full name (e.g. sarcosine, ornithine, etc.), frequently employed three- or four-character codes are employed for residues thereof, including, Sar or Sarc (sarcosine, i.e. N-methylglycine), Alb (a-aminoisobutyric acid), Dab (2,4-diaminobutanoic acid), Dapa (2,3-diaminopropanoic acid), y-Glu (y-glutamic acid), Gaba (y-aminobutanoic acid), P-Pro (pyrrolidine-3-carboxylic acid), and 8Ado (8-amino-3,6-dioxaoctanoic acid), .Abu (2-amino butyric acid), phPro (p-homoproline), piiPhe (p-homophenylalanine) and Bip (P,p di phenyl alanine), and Ida (Iminodiacetic acid).
As is clear to the skilled artisan, the peptide sequences disclosed herein are shown proceeding from left to right, with the left end of the sequence being the N-terminus of the peptide and the right end of the sequence being the C-terminus of the peptide. Among sequences disclosed herein are sequences incorporating a “Hy-” moiety at the amino terminus (N-terminus) of the sequence, and either an “—OH” moiety or an “—NH2” moiety at the carboxy terminus (C-terminus) of the sequence. In such cases, and unless otherwise indicated, a “Hy-” moiety at the N-terminus of the sequence in question indicates a hydrogen atom, corresponding to the presence of a free primary or secondary amino group at the N-terminus, while an “—OH” or an “—NH2” moiety at the C-terminus of the sequence indicates a hydroxy group or an amino group, corresponding to the presence of an amido (CONH2) group at the C-terminus, respectively. In each sequence of the invention, a C-terminal “—OH” moiety may be substituted for a C-terminal “—NH2” moiety, and vice- versa. The term “NH2,” as used herein, refers to a free amino group present at the amino terminus of a polypeptide. The term “OH,” as used herein, refers to a free carboxy group present at the carboxy terminus of a peptide. Further, the term “Ac,” as used herein, refers to Acetyl protection through acylation of the C- or N-terminus of a polypeptide. The term “carboxy,” as used herein, refers to —CO2H. The term “isostere replacement,” as used herein, refers to any amino acid or other analog moiety having chemical and/or structural properties similar to a specified amino acid. The term “pharmaceutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the peptides or compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate,
persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate, and undecanoate. Also, amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. A pharmaceutically acceptable salt may suitably be a salt chosen, e.g., among acid addition salts and basic salts. Examples of acid addition salts include chloride salts, citrate salts and acetate salts. Examples of basic salts include salts where the cation is selected among alkali metal cations, such as sodium or potassium ions, alkaline earth metal cations, such as calcium or magnesium ions, as well as substituted ammonium ions, such as ions of the type N(R1)(R2)(R3)(R4)+, where R1, R2, R3 and R4 independently will typically designate hydrogen, optionally substituted C1-6-alkyl or optionally substituted C2-6-alkenyl. Examples of relevant C1-6-alkyl groups include methyl, ethyl, 1-propyl and 2-propyl groups. Examples of C2-6-alkenyl groups of possible relevance include ethenyl, 1-propenyl and 2-propenyl. Other examples of pharmaceutically acceptable salts are described in “Remington's Pharmaceutical Sciences”, 17th edition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., USA, 1985 (and more recent editions thereof), in the “Encyclopaedia of Pharmaceutical Technology”, 3rd edition, James Swarbrick (Ed.), Informa Healthcare USA (Inc.), NY, USA, 2007, and in J. Pharm. Sci. 66: 2 (1977). Also, for a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002). Other suitable base salts are formed from bases which form non-toxic salts. Representative examples include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, and zinc salts. Hemisalts of acids and bases may also be formed, e.g., hemisulphate and hemicalcium salts. The term “alkyl” includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n- pentyl, n-hexyl, and the like, while saturated branched alkyls include, without limitation,
isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. Representative saturated, cyclic alkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, while unsaturated cyclic alkyls include, without limitation, cyclopentenyl, cyclohexenyl, and the like.
The term “mammal” refers to any mammalian species such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.
As used herein, a “therapeutically effective amount” of the peptide inhibitor of the invention is meant to describe a sufficient amount of the peptide inhibitor to treat a. coronavirus infection (e.g., Covid- 19). In particular embodiments, the therapeutically effective amount will achieve a desired benefit/risk ratio applicable to any medical treatment.
An “analog” of an amino acid, e.g., a “Phe analog” or a “Tyr analog” means an analog of the referenced amino acid. A variety of amino acid analogs are known and available in the art, including Phe and Tyr analogs. In certain embodiments, an amino acid analog, e.g., a. Phe analog or a Tyr analog comprises one, two, three, four or five substitutions as compared to Phe or Tyr, respectively. In certain embodiments, the substi tutions are present in the side chai ns of the amino acids. In certain embodiments, a Phe analog has the structure Phe(R2), wherein R2 is a Hy, OH, CEE, CO2H, CONH2, CONH2OCH2CH2NH2, t-Bu, OCH2CH2NH2, phenoxy, OCH3, OAHyl, Br, Cl, F, Ni l :, N3, or guanadino. In certain embodiments, R2 is CONH2OCH2CH2NH2, OCH3, CONH2, OCH3 or CO2H. Examples of Phe analogs include, but are not limited to: hPhe, Phe(4- OMe), a-Me-Phe, hPhe(3,4-dimethoxy), Phetd-CONth), Phe(4-phenoxy), Phe(4- guanadino), Phe(4-tBu), Phe(4-CN), Phe(4-Br), Phe(4-OBzl), Phe(4-NH2), BhPhe(4-F), Phe(4-F), Phe(3,5 DiF), Phe(Cl b.CO -H).. Phe(penta-F), Phe(3,4-Ch), Phe (3,4-F2), Phe(4- CF3), pP-diPheAla, Phe(4-N?), Phe[4-(2-aminoethoxy)J, 4-Phenylbenzylalanine, Phe(4- CONH2), Phe(3,4-Di methoxy), Phe(4-CF3), Phe(2,3-Ch), and Phe(2,3-F2). Examples of Tyr analogs include, but are not limited to: hTyr, N-Me-Tyr, Tyr(3-tBu), Tyr(4-Nj) and phTyr.
Peptides
Disclosed herein are isolated peptides derived, from an examination of the interaction of a coronavirus spike protein and the angiotensin-converting enzyme 2 protein (ACE2), which is the viral entry receptor for coronaviral infections. As disclosed herein, certain residues of ACE2 served as contact residues for the spike protein and followed the
sequence motif EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX1DKX2X3HE (SEQ ID NO: 22). Accordingly, disclosed herein are peptides comprising the sequence EDX1X2YQ; wherein X1 is L, A, I, V, G, or P; and wherein X2 is F, Y, or W (for example, EDAFYQ EDLFYQ, EDLYYQ, EDAFYQ, EDAYYQ, EDAWYQ, EDIFYQ, EDIYYQ, EDIWYQ, EDLVFYQ, EDVYYQ, EDVWYQ, EDGFYQ, EDGYYQ, EDGWYQ, EDPFYQ, EDPYYQ, OR EDPWYQ), . For example, disclosed herein are peptides, wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. Also disclosed herein are isolated peptides, wherein the peptide comprises the sequence LX1X2MY; wherein X1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M (such as, for example, peptides consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17 as well as, peptides comprising or consisting of LAQMY, LASMY, LATMY, LACMY, LANMY, LAMMY, LIQMY, LISMY, LITMY, LICMY, LINMY, LIMMY, LVQMY, LVSMY, LVTMY, LVCMY, LVNMY, LVMMY, LLQMY, LLSMY, LLTMY, LLCMY, LLNMY, LLMMY, LGQMY, LGSMY, LGTMY, LGCMY, LGNMY, LGMMY). In some aspects, disclosed herein are isolated peptides, wherein the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M .For example, disclosed herein are isolated peptides, wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. The disclosed peptides can be between 6 and 30 amino acids in length, between 10 and 30 amino acids in length. For example, is some aspects the isolated peptides are 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,or 30 amino acids long. In one aspect, the disclosed peptides do not include naturally occurring peptides. Therefore, disclosed herein are isolated peptides of any preceding aspect, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; wherein the peptide comprises the sequence LX1X2MY; and wherein the peptide does not comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.; or wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14
It is understood and herein contemplated that the disclosed peptides can be prepared in a composition with a pharmaceutically acceptable excipient. Thus, in one aspect disclosed herein are composition comprising one or more of the isolated peptides disclosed herein. For example, the composition can comprise any 6-30 amino acid long peptides comprising the sequence motif as set forth in EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX1DKX2X3HE (SEQ ID NO: 22). In one aspect, the peptide of the composition can consist of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or-SEQ ID NO: 19. It is understood and herein contemplated that the combination of multiple differnt peptides in a single composition can have synergistic effect on the ability to inhibit viral entry by a spike protein, inhibit infection, treat an ongoing infection, and/or provide benefits for longer term sequalae of infection. Thus, in one aspect, disclosed herein are compositions comprising any combination of two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, ninetheen or more of the isolated peptides as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and-SEQ ID NO: 19. It is understood and herein contemplated that the disclosed compositions are useful in the treatment and prevention of coronaviral infections. Thus, in one aspect, disclosed herein are any composition disclosed herein further comprising one or more antiviral agents (such as, for example, Remdesivir and/or an anti-coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof). It is further understood and herein contemplated that the dislosed peptides and compositions can be useful in the generation of antibody responses to the spike protein. In particular, the peptides (such as, for example SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and-SEQ ID NO: 19) and compositions disclosed herein comprising said peptides can cause the virus to
agglutinate at the viral entry receptor. This leads to the generation of IgA and IgM antibodies and can also provide a vehicle for enhanced endogenous T cell responses (including, but not limited to TH1 and TH2 CD4 T cells responses, the generation and/or activation of CD8 effector T cells, and/or the activation of CD8 memory T cells). Thus, in one aspect, disclosed herein are methods of stimulating and/or enhancing an endogenous immune response in a subject to a coronavirus comprising administereing to the subject one or more of the peptides and/or compositions disclosed herein. In one aspect the stimulated and/or enhanced endogenous immune response is an IgA or IgM response. In one aspect, the stimulated and/or enhanced endogenous immune response is a CD4 and/or CD8 T cell response. The disclosed peptides and compositions can be useful in pharmaceutical uses, but also propylitic use such as disinfectant, surface cleaner or in livestock building ventilation systems etc. Thus, disclosed herein are disinfectant, surface cleaners, airfilters, and detergents for cleaning humans, livestock, and/or companion animals comprising any of the peptides or compositions disclosed herein. Pharmaceutical Compositions When employed as pharmaceuticals, the peptides and compositions provided herein can be administered in the form of pharmaceutical compositions. These compositions can be prepared as described herein or elsewhere, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal administration), oral, or parenteral. In some embodiments, the composition can be formulated and administered a nasal spray or mist. In some embodiments, the composition can be formulated to deliver the peptides and compositions described herein to the nasal passageways of a subject. In some embodiments, the composition can be formulated to deliver the peptides and compositions described herein to the upper respiratory tract of a subject. In some embodiments, the composition can be formulated to deliver the peptides and compositions described herein to the lower respiratory tract of a subject. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, (e.g., intrathecal or
intraventricular, administration). Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. In some embodiments, the compounds provided herein, or a pharmaceutically acceptable salt thereof, are suitable for parenteral administration. In some embodiments, the compounds provided herein are suitable for intravenous administration. In some embodiments, the compounds provided herein are suitable for oral administration. In some embodiments, the compounds provided herein are suitable for topical administration. Pharmaceutical compositions and formulations for topical administration may include, but are not limited to, transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. In some embodiments, the pharmaceutical compositions provided herein are suitable for parenteral administration. In some embodiments, the pharmaceutical compositions provided herein are suitable for intravenous administration. In some embodiments, the pharmaceutical compositions provided herein are suitable for oral administration. In some embodiments, the pharmaceutical compositions provided herein are suitable for topical administration. In some embodiments, the composition can comprise a nasal spray or mist. In some embodiments, the composition can be a formulation for use in irrigation of nasal passageways. Also provided are pharmaceutical compositions which contain, as the active ingredient, a compound provided herein in combination with one or more pharmaceutically acceptable carriers (e.g. excipients). In making the pharmaceutical compositions provided herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be, for example, in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. Some examples of suitable excipients include, without limitation, lactose, dextrose, xylitol, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone,
cellulose, water, syrup, and methyl cellulose. The formulations can additionally include, without limitation, lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; flavoring agents, or combinations thereof. The active compound can be effective over a wide dosage range and is generally administered in an effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual subject, the severity of the subject’s symptoms, and the like. The compositions provided herein can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including, but not limited to, the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a compound described herein can include a single treatment or a series of treatments. Dosage, toxicity and therapeutic efficacy of the compounds provided herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds exhibiting high therapeutic indices are preferred. While compounds that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects. In some embodiments, the compositions described herein may further contain (or be administered in combination or alternation with) one or more additional active agents. Representative examples additional active agents include agents for the treatment and/or prevention of coronavirus infections such as SARS-CoV-2 infections (e.g., an anti- coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof), other antimicrobial agents (including antibiotics, antiviral agents and anti-fungal agents), anti-inflammatory agents (including
steroids and non-steroidal anti-inflammatory agents), anti-coagulant agents, immunomodulatory agents, anticytokine, antiplatelet agents, and antiseptic agents. Representative examples of antibiotics include amikacin, amoxicillin, ampicillin, atovaquone, azithromycin, aztreonam, bacitracin, carbenicillin, cefadroxil, cefazolin, cefdinir, cefditoren, cefepime, cefiderocol, cefoperazone, cefotetan, cefoxitin, cefotaxime, cefpodoxime, cefprozil, ceftaroline, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, chloramphenicol, colistimethate, cefuroxime, cephalexin, cephradine, cilastatin, cinoxacin, ciprofloxacin, clarithromycin, clindamycin, dalbavancin, dalfopristin, daptomycin, demeclocycline, dicloxacillin, doripenem, doxycycline, eravacycline, ertapenem, erythromycin, fidaxomicin, fosfomycin, gatifloxacin, gemifloxacin, gentamicin, imipenem, lefamulin, lincomycin, linezolid, lomefloxacin, loracarbef, meropenem, metronidazole, minocycline, moxifloxacin, nafcillin, nalidixic acid, neomycin, norfloxacin, ofloxacin, omadacycline, oritavancin, oxacillin, oxytetracycline, paromomycin, penicillin, pentamidine, piperacillin, plazomicin, quinupristin, rifaximin, sarecycline, secnidazole, sparfloxacin, spectinomycin, sulfamethoxazole, sulfisoxazole, tedizolid, telavancin, telithromycin, ticarcillin, tigecycline, tobramycin, trimethoprim, trovafloxacin, and vancomycin. Representative examples of antiviral agents include, but are not limited to, abacavir, acyclovir, adefovir, amantadine, amprenavir, atazanavir, balavir, baloxavir marboxil, boceprevir, cidofovir, cobicistat, daclatasvir, darunavir, delavirdine, didanosine, docasanol, dolutegravir, doravirine, ecoliever, edoxudine, efavirenz, elvitegravir, emtricitabine, enfuvirtide, entecavir, etravirine, famciclovir, fomivirsen, fosamprenavir, forscarnet, fosnonet, famciclovir, favipravir, fomivirsen, foscavir, ganciclovir, ibacitabine, idoxuridine, indinavir, inosine, inosine pranobex, interferon type I, interferon type II, interferon type III, lamivudine, letermovir, letermovir, lopinavir, loviride, maraviroc, methisazone, moroxydine, nelfinavir, nevirapine, nitazoxanide, oseltamivir, peginterferon alfa-2a, peginterferon alfa-2b, penciclovir, peramivir, pleconaril, podophyllotoxin, pyramidine, raltegravir, remdesevir, ribavirin, rilpivirine, rimantadine, rintatolimod, ritonavir, saquinavir, simeprevir, sofosbuvir, stavudine, tarabivirin, telaprevir, telbivudine, tenofovir alafenamide, tenofovir disoproxil, tenofovir, tipranavir, trifluridine, trizivir, tromantadine, umifenovir, valaciclovir, valganciclovir, vidarabine, zalcitabine, zanamivir, and zidovudine.
Representative examples of anticoagulant agents include, but are not limited to, heparin, warfarin, rivaroxaban, dabigatran, apixaban, edoxaban, enoxaparin, and fondaparinux. Representative examples of antiplatelet agents include, but are not limited to, clopidogrel, ticagrelor, prasugrel, dipyridamole, dipyridamole/aspirin, ticlopidine, and eptifibatide. Representative examples of antifungal agents include, but are not limited to, voriconazole, itraconazole, posaconazole, fluconazole, ketoconazole, clotrimazole, isavuconazonium, miconazole, caspofungin, anidulafungin, micafungin, griseofulvin, terbinafine, flucytosine, terbinafine, nystatin, and amphotericin b. Representative examples of steroidal anti-inflammatory agents include, but are not limited to, hydrocortisone, dexamethasone, prednisolone, prednisone, triamcinolone, methylprednisolone, budesonide, betamethasone, cortisone, and deflazacort. Representative examples of non-steroidal anti-inflammatory drugs include ibuprofen, naproxen, ketoprofen, tolmetin, etodolac, fenoprofen, flurbiprofen, diclofenac, piroxicam, indomethacin, sulindax, meloxicam, nabumetone, oxaprozin, mefenamic acid, and diflunisal. Other examples of additional active agents include chloroquine, hydrochloroquine, Vitamin D, and Vitamin C. Methods of Use As noted above, the disclosed compositions and peptides are useful in the treatment and prevention of coronaviral infections. Specifically, the disclosed peptides can disrupt and otherwise inhibit viral entry into a cell via ACE2. Thus, in one aspect, disclosed herein are method of inhibiting, reducing, decreasing, and/or preventing viral entry (such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV), turkey bluecomb
coronavirus (TCoV), human coronavirus (HCoV)-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) (SARS- CoV), Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV)-2 (SARS-CoV-2) (including, but not limited to the B1.351 variant, B.1.1.7 variant, USA-WA1/2020, or P.1 variant), or middle east respiratory syndrome (MERS) coronavirus (CoV) (MERS-CoV)) in a cell of a subject comprising administering to the subject a therapeutically effective amount of the isolated peptides disclosed herein or a therapeutically effective amount of any of the compositions disclosed herein; wherein the viral entry receptor comprises human angiotensin-converting enzyme 2 (ACE2). For example, for the inhibition, reduction, and/or prevetntion of viral entry of a coronavirus, the subject can be administered a therapeutically effective amount of peptides comprising the sequence EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX1DKX2X3HE (SEQ ID NO: 22). In some aspects, peptide for use in the disclosed methods of inhibiting viral entry comprise the sequence EDX1X2YQ; wherein X1 is L, A, I, V, G, or P; and wherein X2 is F, Y, or W. For example, disclosed herein are methods of inhibiting viral entry, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. Also disclosed herein are methods of inhibiting viral entry, wherein the peptide comprises the sequence LX1X2MY; wherein X1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M (such as, for example, peptides consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17). Also disclosed herein are methods of inhibiting viral entry, wherein the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M .For example, the peptide can comprise the sequence TFX1DKX2X3HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. In some aspects, the methods of inhibiting viral entry do not use a naturally occurring peptide alone, but can comprise the use of multiple naturally occurring peptides in a composition or one or more naturally occurring peptides in combination with an antiviral agent. Thus, disclosed herein are methods of inhibiting viral entry wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; wherein the peptide comprises the sequence LX1X2MY; and wherein the peptide does not
comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.; or wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. It is understood that the administration of the disclosed peptides and/or compositions can occur for therapeutic intervention or prophylactic uses. Thus, in one aspect, the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus. Also disclosed herein are methods of treating, inhibiting, reducing, decreasing, and/or preventing a viral infection (such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV), turkey bluecomb coronavirus (TCoV), human coronavirus (HCoV)-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) (SARS-CoV), Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV)-2 (SARS-CoV-2) (including, but not limited to the B1.351 variant, B.1.1.7 variant, USA-WA1/2020, or P.1 variant), or middle east respiratory syndrome (MERS) coronavirus (CoV) (MERS-CoV)) in a subject comprising administering to the subject a therapeutically effective amount of the isolated peptides of any peptide disclosed herein or a therapeutically effective any composition disclosed herein. For example, disclosed herein are methods of treating, inhibiting, reducing, decreasing, and/or preventing a coronaviral infection comprising administering to the subject a therapeutically effective amount of peptides comprising the sequence EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX1DKX2X3HE (SEQ ID NO: 22). In some aspects, peptide for use in the disclosed methods of treating, inhibiting, reducing, decreasing, and/or preventing a coronaviral infection comprise the sequence EDX1X2YQ; wherein X1 is L, A, I, V, G, or P; and wherein X2 is F, Y, or W. For example, disclosed herein are methods of treating, inhibiting, reducing, decreasing, and/or preventing a coronaviral infection, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide consists of SEQ
ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. Also disclosed herein are methods of treating, inhibiting, reducing, decreasing, and/or preventing a coronaviral infection, wherein the peptide comprises the sequence LX1X2MY; wherein X1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M (such as, for example, peptides consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17). Also disclosed herein are methods of treating, inhibiting, reducing, decreasing, and/or preventing a coronaviral infection, wherein the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M. For example, the peptide used in the disvlosed methods can comprise the sequence TFX1DKX2X3HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. In some aspects, the methods of inhibiting, reducing, decreasing, and/or preventing a coronaviral infection do not use a naturally occurring peptide alone, but can comprise the use of multiple naturally occurring peptides in a composition or one or more naturally occurring peptides in combination with an antiviral agent. Thus, isclosed herein are methods of inhibiting, reducing, decreasing, and/or preventing a coronaviral infection wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; wherein the peptide comprises the sequence LX1X2MY; and wherein the peptide does not comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.; or wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. It is understood that the administration of the disclosed peptides and/or compositions can occur for therapeutic intervention or prophylactic uses. Thus, in one aspect, the disclosed compositions and/or peptides can be administered to the subject prior to or following exposure to or infection with the virus. In one aspect, the treatment of the coronaviral infection is not limited to inhibition, reduction, and/or amelioration of the actual infection, but also includes a inhibition, reduction, and/or amelioration of symptoms and long term residual complications and effects resulting from the infection (e.g., post-COVID-syndrome), such symptoms and/or complications including, but not limited to reduced sense of smell and/or taste, memory loss, fatigue, shortness of breath, cough, joint pain, difficulty concentrating, depression,
muscle pain, headache, rapid heartbeat, Postural orthostatic tachycardia syndrome, diabetes, and intermittent fever. The administration of any of the peptides and/or compositions disclosed herein can be used to prevent, inhibit, reduce, ameliorate, and/or alleviate any one or combination of these symptoms in a subject with an active coronaviral infection as well as after clearance of said infection. Thus, in one aspect, disclosed herein are methods of treating, inhibiting, reducing, ameliorating, alleviating, and/or preventing one or more symptoms or post-infection complications (such as, for example, reduced sense of smell and/or taste, memory loss, fatigue, shortness of breath, cough, joint pain, difficulty concentrating, depression, muscle pain, headache, rapid heartbeat, Postural orthostatic tachycardia syndrome, diabetes, and intermittent fever) of a coronalviral infection such as, for example, entry of a coronavirus including, but not limited to avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV), turkey bluecomb coronavirus (TCoV), human coronavirus (HCoV)-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) (SARS- CoV), Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV)-2 (SARS-CoV-2) (including, but not limited to the B1.351 variant, B.1.1.7 variant, USA-WA1/2020, or P.1 variant), or middle east respiratory syndrome (MERS) coronavirus (CoV) (MERS-CoV)) comprising administering to the subject a therapeutically effective amount of peptides comprising the sequence EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX1DKX2X3HE (SEQ ID NO: 22) and/or compositions disclosed herein comprising said peptides. In some aspects, peptide for use in the disclosed methods of treating, inhibiting, reducing, ameliorating, alleviating, and/or preventing one or more symptoms or post-infection complications of a coronaviral infection comprise the sequence EDX1X2YQ; wherein X1 is L, A, I, V, G, or P; and wherein X2 is F, Y, or W. For example, disclosed herein are methods of treating, inhibiting, reducing, ameliorating, alleviating, and/or preventing one or more symptoms or post-infection complications of a coronaviral infection, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide
consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. Also disclosed herein are methods of treating, inhibiting, reducing, ameliorating, alleviating, and/or preventing one or more symptoms or post-infection complications of a coronaviral infection, wherein the peptide comprises the sequence LX1X2MY; wherein X1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M (such as, for example, peptides consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17). Also disclosed herein are methods of treating, inhibiting, reducing, ameliorating, alleviating, and/or preventing one or more symptoms or post-infection complications of a coronaviral infection, wherein the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M. For example, the peptide used in the disvlosed methods can comprise the sequence TFX1DKX2X3HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. EXAMPLES The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non- critical parameters which can be changed or modified to yield essentially the same results. Example 1: Rationally designed ACE2-derived peptides inhibit SARS-CoV-2. Overview Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 is a novel and highly pathogenic coronavirus and is the causative agent of the coronavirus disease 2019 (COVID- 19). The high morbidity and mortality associated with COVID-19 and the limited SARS- CoV-2 underscores the urgent need for developing effective antiviral therapies. Therapeutics that target essential viral proteins are effective at controlling virus replication and spread. Coronavirus Spike glycoproteins mediate viral entry and fusion with the host cell, and thus, are essential for viral replication. To enter host cells, the Spike proteins of SARS-CoV-2 and related coronavirus, SARS-CoV, bind the host angiotensin-converting enzyme 2 (ACE2) receptor through their receptor binding domains (RBDs). In this example, a panel of ACE2-derived peptides were designed based on the RBD-ACE2 binding
interfaces of SARS-CoV-2 and SARS-CoV. Using SARS-CoV-2 and SARS-CoV Spike- pseudotyped viruses, subset of peptides were found to inhibit Spike-mediated infection with IC50 values in the low millimolar range. Two peptides were found that bound Spike RBD in affinity precipitation assays and inhibited infection with genuine SARS-CoV-2. Moreover, these peptides inhibited the replication of a common cold causing coronavirus, which also uses ACE2 as its entry receptor. Results from the infection experiments and modeling of the peptides with Spike RBD identified a six amino acid (Glu37-Gln42) ACE2 motif that is important for SARS-CoV-2 inhibition. These studies demonstrate the feasibility of inhibiting SARS-CoV-2 with peptide-based inhibitors. These findings allow for the successful development of engineered peptides and peptidomimetic-based compounds for the treatment of COVID-19. Background Of the seven coronaviruses known to infect humans, SARS-CoV-2 and two other highly pathogenic coronaviruses, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), are the result of zoonotic transmission. Sequence analyses of coronaviruses have revealed that the SARS-CoV-2 genome shares ~80% identity with SARS-CoV and ~96% identity with bat coronavirus RaTG13. Similar to all coronaviruses, SARS-CoV-2 virions display the characteristic club-shaped projections formed by trimers of viral Spike glycoprotein on their surface. Spike proteins are essential for viral replication as they mediate viral entry into the host cell. During virion morphogenesis, the trimeric Spike protein is cleaved into the S1 and S2 subunits. The cleavage event positions the receptor-binding domain (RBD) in the S1 subunits in a receptor-accessible conformation and induces structural changes in the S2 subunits to stabilize its prefusion state. SARS-CoV and SARS-CoV-2 RBDs bind to the peptidase domain of human angiotensin-converting enzyme 2 (ACE2), which serves as the viral entry receptor. Binding of the RBD to ACE2 triggers another cleavage event of the S2 subunit, which results in formation of the six-helix bundle fusion core necessary for viral-host membrane fusion. The essential role of Spike protein in receptor binding and viral fusion makes it a target for vaccine candidate development and therapeutic interventions. Seminal SARS-CoV and SARS-CoV-2 structural studies have revealed the overall structures of Spike trimers, detailed atomic level structures of RBD bound to ACE2, and structural intermediates of the Spike-ACE2 interaction events. These structural studies have identified that SARS-CoV and SARS-CoV-2 Spikes bind ACE2 with a nearly identical
binding mode – the N-terminal lobe of the ACE2 peptidase domain binds a concave groove on the Spike RBD. Moreover, these studies highlighted that SARS-CoV and SARS-CoV-2 have conserved interactions at the RBD-ACE2 binding interface. For example, 17/20 contacting amino acid residues in ACE2 have conserved interactions with the two RBDs. Likewise, 13/14 contacting residues in the two RBDs are either conserved or have conservatively substituted side chains. Given the significance of the RBD-ACE2 interaction interface for SARS-CoV-2 infection, computational approaches have identified potential inhibitory peptides that could interfere with the interaction of Spike protein with ACE2. These theoretical studies have suggested that regions in Spike and select residues in ACE2 could be exploited for competitive inhibition. While potentially promising, the antiviral potential of such peptides have not been experimentally evaluated. In this example, we performed comparative analyses of the SARS-CoV and SARS- CoV-2 RBD-ACE2 interaction interfaces to rationally design a panel of Spike-targeting ACE2-derived peptides (SAPs). A combination of approaches were used to evaluate the inhibitory potential, selective inhibition, and binding affinity of SAPs. Antiviral potential of selected SAPs was validated against two pathogenic human coronaviruses, SARS-CoV-2 and HCoV-NL63, both of which use ACE2 as entry receptors. Importantly, these findings provide a proof-of-principle and demonstrate feasibility of inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors Materials and Methods Peptide design and recombinant proteins. SAPs were designed using the following published structures: SARS-CoV-2 Spike S1 subunit bound to ACE2 (PDB codes: 7A91-98), SARS-CoV-2 RBD bound to ACE2 (PDB codes: 6M0J and 6VW1), SARS-CoV RBD bound to ACE2 (PDB code: 2AJF), and SARS-CoV S1-S2 subunits bound to ACE2 (PDB codes: 6ACK, 6ACJ, 6ACC, 6ACD, and 6ACG). Sequence and structural comparisons of the SARS-CoV and SARS-CoV-2 binding interfaces with ACE2 were performed using Clustal Omega (EMBL-EBI, England), SWISS-MODEL (Biozentrum, Switzerland), and MUSTER (University of Michigan, USA). Once designed, synthetic SAPs were purchased from Biomatik (95% purity, with TFA removed) either unmodified or with an N-terminal FITC label (FITC-SAP). 1X Phosphate Buffered Saline (PBS) was used as a diluent to reconstitute SAPs. To improve the solubility of SAP1 and SAP2, 1X PBS was supplemented with 10% and 5% aqueous NH3, respectively.
Recombinant His-tagged SARS-CoV-2 Spike RBD (His-S RBD, amino acids Arg319- Phe541) was purchased from RayBiotech. Affinity precipitation assay. Affinity precipitation assays using Ni-NTA beads (GE Healthcare) were performed with His-S RBD and FITC-SAPs using known methods. Briefly, Ni-NTA beads were equilibrated in binding buffer (50 mM Tris pH 7.5, 250 mM NaCl, 50 mM LPLGD]ROH^^DQG^^^P0^ȕ-mercaptoethanol). Binding reactions were setup by incubating equilibrated Ni-NTA beads with His-S RBD (1 μM) and increasing concentrations (3, 1, 0.5, 0.25, and 0.125 mM) of indicated FITC-SAP in the binding buffer and incubated for 1 h at 4ºC. In parallel, control reactions with 3 mM of indicated FITC- SAP without His-S RBD were preformed to rule out non-specific FITC-SAP binding to the Ni-NTA beads. Reactions were spun and washed three times in the binding buffer to remove unbound proteins/peptides. The resulting protein-peptide complexes bound to the beads were extracted using NuPAGE lithium dodecyl sulfate sample buffer (Invitrogen), subjected to SDS-PAGE analysis, and visualized by Coomassie staining or fluorescence detection at 488 nm. Resulting FITC-labeled bands were quantified using ImageJ software. To estimate Kd values for FITC-SAP binding to His-S RBD, the data were fit to the Hill equation using Origin 8 software (OriginLab). Cells, plasmids, viruses. HEK293T (ATCC CRL-3216), HEK293T-ACE2 (BEI Resources), Vero E6 (ATCC CRL-1586), and LLC-MK2 (ATCC CCL-7) cells were cultured in Dulbecco's modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco). HEK293T cells stably expressing GFP-tagged human ACE2 (HEK293T-ACE2-GFP) were generated using known methods, and were maintained in DMEM supplemented with 10% FBS and 1 μg/mL puromycin (Sigma). Plasmid encoding SARS-CoV-2 Spike (pCAGGS-SARS-CoV-2 Spike) was obtained from BEI Resources. Generation of plasmid encoding SARS-CoV Spike (pCAGGS-SARS-CoV Spike) has been described previously. Vesicular stomatitis virus-G (VSV-G) expression plasmid (pMD2.G) was purchased from Addgene. HIV-1-derived luciferase reporter vector (pNL4-3.Luc.R-E-) was obtained from NIH AIDS Reagent Program. SARS-CoV-2 USA-WA1/2020 stock virus was obtained from BEI Resources. Human coronavirus NL63 (HCoV-NL63) stock was obtained from Dr. Susan Baker (Loyola University, Chicago, IL).
Pseudovirus production. Zz/d/mrs-e-encoding lentiviruses pseudotyped with viral glycoprotein of interest were generated using known methods. Briefly, HEK293T cells were transfected with pNL4-3.Luc.Rl? and pCAGGS-SARS-CoV-2 Spike, pCAGGS-SARS- CoV Spike, or pMD2.G using Fugene 6 transfection reagent (Roche) following manufacturer’s protocol. Forty-eight hours post-transfection, virus-containing supernatants were harvested, filtered through 0.45 pm sterile filter, and concentrated using Ami con Ultra-15 centrifugal filters (Millipore). Aliquots of pseudoviruses were stored at -80°C. The titers of SARS-CoV-2 Spike-, SARS-CoV Spike-, and VSV-G-pseudotyped viruses were in the range of 2 x 105, ~1 x 103, and ~3 x IO7 relative luciferase units (RLUs)/ml, respectively.
Pseudovirus inhibition assay. HEK293T-ACE2 cells were seeded in pCIear Black 96-well plates (Greiner Bio-One) in 100 pl of DMEM supplemented with 10% FBS at a density of 1.25 x 104 cells per well. Sixteen hours after plating, equal amounts (RLUs/ml) of a given pseudovirus were incubated with indicated concentrations of the test peptide or diluent control (IX PBS) in 50 pl of DMEM supplemented with 10% FBS for 1 h at 37°C in a V-bottom 96-well plate. The virus-peptide mixture was then added to the HEK293T- ACE2 cells. Polybrene (Sigma) at the final concentration of 5 pg/ml was added to the cells. After 48 h, 100 pl of supernatant was removed from each well and luciferase activity was measured using Bright-Glo Luciferase Assay System (Promega) following the manufacturer’s protocol. Luminescence was detected using an Infinite M PLEX multimode plate reader (Tecan).
Dose response curves. For dose response curves, the pseudovirus inhibition assays were performed with increasing concentrations of SAP (0.001, 0.01, 0.1, 1.0, 2.5, 5.0, and 7.5 mM). Percent viral inhibition was calculated as the percent reduction in luciferase activity of pseudovirus incubated with a given concentration of SAP compared to the pseudovirus incubated with the diluent control. The concentration of SAP that resulted in 50% inhibition of viral replication (ICso) was interpolated from a non-linear, best-fit curve using GraphPad Prism 8.0.2 software.
Biosafety procedures for live SARS-CoV-2 experiments. All experiments involving live SARS-CoV-2 were performed at Biosafety Level 3 (BSL3) according to the standard operating procedures approved by The Ohio State University BSL3 Operations Group (BOG) and Institutional Biosafety Committee. Infected cells were removed from the BSL3 facility for subsequent analyses after fixation with 4% paraformaldehyde for a
minimum of 1 h in accordance with a validated decontamination protocol approved by the BOG and Institutional Biosafety Officer.
SARS-CoV-2 propagation. SARS-CoV-2 USA-WA1/2020 stock was diluted 1 : 10,000 in DMEM and added to confluent Veto E6 cells. After infection for 1 h at 37°C, media was replaced with DMEM supplemented with 4% FBS. Following incubation at 37°C for 72 h, virus-containing supernatant was clarified at 1,000 x g for 10 min to remove cell debris, aliquoted, flash frozen in liquid nitrogen, and stored at -80°C. The viral stock titer was determined by plaque assay on Vero E6 cells in 12-well plates with 0.3% low- melting agarose (Sigma) overlay and visualization with 0.25% crystal violet (Sigma).
SARS-CoV-2 infections. 106 plaque-forming units of SARS-CoV -2 were incubated with 3 mM final concentration of the test peptide or diluent control (I X PBS) in 400 pl of DMEM for 1 h at 37°C. The virus-peptide mixture was then added to near-confluent HEK293T-ACE2-GFP cells in a 12-well plate. Infection was allowed to proceed for 1 h at 37°C at which point media was removed and replaced with 500 pl of DMEM supplemented with 10% FBS, After 24 h, the cells were harvested using 0.25% trypsin-EDTA (Gibco), fixed with 4% paraformaldehyde (Thermo Scientific) for 1 h at room temperature, permeabilized with IX PBS containing 0.1% Triton X-100, and blocked with IX PBS containing 2% FBS. The cells were then stained with anti -SARS-CoV-2 N mouse monoclonal antibody (1 : 1000, Sino Biological) followed by staining with anti-mouse AlexaFluor-647 secondary antibody (1 : 1000, Life Technologies). The stained cells were analyzed using a FACSCanto II flow cytometer (BD Biosciences). Flow cytometry data was analyzed using FlowJo software.
HCoV-NL63 propagation. HCoV-NL63 stock was expanded and titered on LLC- MK2 cells using previously described methods. The virus was aliquoted and stored at - 80°C.
HCoV-NL63 infections. HCoV~NL63 equivalent to MOI of 0.5 was incubated with 3 mM final concentration of the test peptide or diluent control (IX PBS) in 300 pl of DMEM for 1 h at 37°C. Confluent LLC-MK2 cells in 6-well plates were washed once with DMEM. The virus-peptide mixture was then added to LLC-MK2 cells in triplicate. Infection was allowed to proceed for 1 h at 37°C at which point media was removed and replaced with 1 ml of DMEM: supplemented with 2% FBS. After 72 h, the cytopathic effects (CPE) in each well were imaged under a light microscope. The cell culture supernatants were collected for virus titration by plaque assay.
HCoV~NL63 plaque assay. Confluent LLC-MK2 cells in 6-well plates were infected with serial dilutions (ranging from 10'1 to IO"7) of HCoV-NL63 in DMEM. After infection for 1 h at 37°C, cells were washed three times with DMEM and overlaid with 1% low-melting agarose in 2 ml of DMEM supplemented with 2% FBS. After incubation at 37°C for 5 days, cells \vere fixed with 4% paraformaldehyde for 2 h and plaques were visualized after staining with 0.05% crystal violet.
Results and Discussion
Rational design of ACE2-derived peptides. In order to design a panel of small peptide-based inhibitors that can block the interaction of SARS-CoV-2 Spike with the ACE2 receptor, a combination of structural and biochemical data, and known amino acid interactions necessary for binding of SARS-CoV and SARS-CoV-2 Spike proteins to ACE2 were utilized. This included: 1) crystal structures of ACE2 bound to SARS-CoV and SARS- CoV-2 Spike receptor binding domains (RBDs); 2) cryoEM structures of ACE2 in complex with trimeric SARS-CoV Spike and RBD or SI subunit of SARS-CoV-2 Spike; and 3) biochemical binding data of the ACE 2 -interacting motif with the SARS-CoV and SARS- CoV-2 Spikes. In particular, wre focused on the Spike-ACE2 interaction interface as it offers a prime target for competitive inhibition of viral entry. Structural and biochemical analyses suggest that SARS-CoV and SARS-CoV-2 RBDs bind ACE2 with nearly identical binding modes and with similar low nanomolar binding affinities. The al helix of ACE2, which is cradled in a concave groove formed by the p5 and p6 sheets of the RBD, provides the most contacts with the two RBDs (ACE2 residues Gln24, Thr27, Phe28, Lys31, His34, Glu37, Asp38, Tyr41, and Gln42). Additional contacts from ACE2 are provided by a.3 helix (ACE2 residues Leu79, Met82, Tyr83 for the two RBDs), a short loop between alO and al 1 helices (ACE2 residues Gln325 and Glu329 for SARS-CoV RBD and Asn330 for both RBDs), p~ hairpin flanking al 1 helix (ACE2 residue Lys353 for both RBDs), and al 1 helix (ACE2 residues Gly354, Asp355, and Arg357 for both RBDs). Conversely, 14 residues (402, 426, 436, 440, 442, 472, 473, 475, 479, 484, 486, 487, 488, and 491) in the two RBDs provide contacts with ACE2. These RBD residues form a network of hydrogen bonds, salt bridges, and van der Waals contacts with ACE2 residues. Based on these insights, six Spiketargeting ACE2-derived peptides (SAPs) — four derived from al, one derived from a3, and one derived from al l helix of ACE2-— were designed (Table 1). The SAPs were designed using the following criteria: 1) they contain at least three residues predicted to interact with RBDs based on structural data (Table 1, highlighted in bold); 2) they are not highly
disordered or unresolved in the crystal structures (such as ACE2 residues 1-18); and 3) the length is more than six and less than 30 amino acids, making them amenable for synthesis. Table 1. Spike-targeting ACE2-derived peptides (SAPs) used in Example 1. Amino acid sequence with the residue number of the first and last amino acid in the sequence is indicated. The EDLFYQ motif is underlined. The SARS-CoV and SARS-CoV-2 contacting residues are indicated with bold font.
SAPs inhibit SARS-CoV-2 Spike-pseudotyped lentivirus infection. We evaluated the antiviral potencies of SAPs against lentiviral vectors pseudotyped with SARS- CoV-2 Spike glycoprotein. Lentiviral cores pseudotyped with viral surface glycoproteins offer an alternative to highly pathogenic viruses that require biosafety level 3 (BSL3) or BSL4 facilities. Importantly, pseudotyped viruses can be utilized at BSL2 and are ideal for studies pertaining to viral entry and screening of therapeutic agents that target viral entry, such as the peptides in this study. Luciferase-encoding lentiviruses pseudotyped with SARS-CoV-2 Spike were incubated with test peptides to allow binding to the vector particle-associated Spike prior to infection of HEK293T-ACE2 cells. Luciferase production was measured 48 hours post-infection. A titration curve for each peptide was generated for determining its inhibitory concentration (IC50). Of the six SAPs tested, SAP1, SAP2, and SAP6 inhibited SARS-CoV-2 Spike-mediated virus infection with an IC50 value of 2.39 ± 0.20, 3.72 ± 0.37, and 1.90 ± 0.14 mM, respectively (Figure 1). In contrast, 50% inhibition of Spike-mediated virus infection was not achieved with SAP3, SAP4 or SAP5 even at 7.5 mM, the highest concentration tested. Thus, three of the six SAPs inhibit SARS-CoV-2 Spike-mediated virus infection with IC50 values in the low millimolar range. Despite the fact that the genomes of SARS-CoV and SARS-CoV-2 share ~80% sequence identity and most of the sequence variation is within the Spike open reading frame, the overall structure and ACE2-binding mode of their Spike RBDs are nearly identical. Moreover, the majority of amino acid residues in the SARS-CoV and SARS-CoV- 2 RBDs that are essential for binding ACE2 are either identical or have conserved side chains. Thus, we sought to determine whether SAPs that inhibit SARS-CoV-2 Spike- mediated virus infection are also able to inhibit infection mediated by SARS-CoV Spike. For this, SAPs with positive inhibitory profiles from Figure 1 were evaluated for their ability to inhibit infection of SARS-CoV Spike- and SARS-CoV-2 Spike-pseudotyped viruses at 3 mM dose, which is within the IC50 range for the test peptides (Figure 1). As specificity control, antiviral activity of SAPs was also measured against lentiviruses pseudotyped with vesicular stomatitis virus Glycoprotein (VSV-G), which utilizes low- density lipoprotein receptor, LDL-R for viral entry. In comparison to the diluent control, SAP1, SAP2, and SAP6 treatment resulted in ~1.6–3.5-fold reduction in SARS-CoV-2 Spike-mediated infection (Figure 2A) and ~1.9–7.5-fold reduction in SARS-CoV Spike- mediated infection (Figure 2B). Consistent with the results in Figure 1, SAP5 treatment had no significant effect on SARS-CoV-2 Spike-mediated infection, but resulted in ~1.5-fold
reduction in SARS-CoV Spike-mediated infection. None of the SAPs affected VSV-G- mediated virus infection demonstrating their specificity for inhibiting Spike-mediated viral entry (Figure 2C). The slightly higher potency of SAP1, SAP5, and SAP6 against SARS- CoV Spike-mediated infection compared to SARS-CoV-2 Spike-mediated infection could be attributable to subtle differences in the SARS-CoV and SARS-CoV-2 RBD-ACE2 interaction interfaces. Importantly, these results highlight the fact that minor differences in the number of contact residues and their interactions at the RBD-ACE2 interface could be exploitable for structure-based rational design of viral-specific inhibitors. Binding affinities of SAPs to SARS-CoV-2 Spike RBD. Recent studies using biochemical and biophysical methods have demonstrated that the RBD within the S1 subunit of SARS-CoV-2 Spike is responsible for binding ACE2 with high affinity. Thus, we employed affinity precipitation assays to determine the binding affinities of SAPs with positive inhibitory profiles to recombinantly expressed and purified Spike RBD. A titration curve for each FITC-labeled peptide was generated for determining its binding affinity to His-tagged Spike RBD (Figure 3 A and B). Of the four SAPs tested, SAP1 displayed the highest binding affinity (Kd = 0.53 ± 0.01 mM) whereas SAP5 did not display any detectable binding in vitro (Figure 3B). SAP6, which contains the overlapping region in SAP1 and SAP2 (Table 1), displayed binding affinity similar to SAP1 (Figure 3C, SAP6 Kd of 1.36 ± 0.14 mM vs SAP1 Kd = 0.53 ± 0.01 mM). SAP2 displayed lower binding (Kd = 10.7 ± 4.2 mM) possibly attributable to the presence of two consecutive serine residues in the peptide, which could affect its flexibility. Thus, our results suggest that SAP6 contains the minimal residues needed for binding RBD and additional residues in SAP1 can slightly improve the binding affinity. Moreover, we found that the in vitro binding affinities of SAPs track closely with their antiviral IC50 values (Figures 1 and 3). SAP1 and SAP6 inhibit SARS-CoV-2 infection. We next sought to determine whether SAPs that bind RBD with high affinity and display positive inhibitory profiles against pseudotyped viruses are also able to inhibit the infection of genuine SARS-CoV-2. To this end, SAP1, SAP5, and SAP6 were evaluated for their ability to inhibit infection of SARS-CoV-2. Viruses was incubated with 3 mM of test peptide or diluent control to allow binding to the virion-associated Spike prior to infection of HEK293T-ACE2-GFP cells. Percent infection was measured by intracellular staining of SARS-CoV-2 N protein and flow cytometry 24 hours post-infection. In comparison to the diluent control, SAP1 and SAP6 treatment resulted in ~2-fold reduction in SARS-CoV-2 infection (Figure 4 A and
B). In contrast, SAP5, which does not bind RBD and does not inhibit SARS-CoV-2 Spike- pseudotyped lentiviruses, had no significant effect on virus infection. Based on the findings that SAP1 and SAP6 have comparable IC50 values (Figure 1), bind RBD with similar affinity (Figure 3C), and inhibit SARS-CoV-2 infection to similar levels (Figure 4B), we conclude that SAP6 contains the minimal necessary residues for inhibition of SARS-CoV-2. SAP1 and SAP6 inhibit HCoV-NL63 infection. In addition to the three highly pathogenic coronaviruses known to infect humans, four low pathogenicity coronaviruses (HCoV-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63) are endemic in humans and cause common cold and upper and lower respiratory tract infections. Of the four endemic human coronaviruses, only HCoV-NL63 uses ACE2 as entry receptor. Similar to SARS- CoV and SARS-CoV-2, the S1 subunit of HCoV-NL63 Spike binds ACE2 to mediate viral entry. Thus, we sought to determine whether SAP1 and SAP6, which inhibit SARS-CoV-2 infection, could also inhibit HCoV-NL63 infection. Viruses were incubated with 3 mM of test peptide or diluent control to allow binding to the virion-associated Spike prior to infection of LLC-MK2 cells. Virus-induced cytopathic effects (CPEs) and virus titers in the supernatants were measured 72 hours post-infection. Severe CPEs were observed in cells that were infected with viruses treated with diluent control or SAP5 indicating robust viral infection (Figure 5A). In contrast, reduced CPEs were observed in cells infected with SAP1- or SAP6-treated viruses indicating reduced viral infection. Moreover, in comparison to the diluent control, SAP1 and SAP6 treatment resulted in ~3-fold reduced HCoV-NL63 titers (Figure 5B). In contrast, SAP5 treatment did not result in significant reduction of viral titers. Taken together, our results demonstrate that SAP1 and SAP6 inhibit infection of SARS-CoV-2 and HCoV-NL63, both of which utilize ACE2 as entry receptor. Structural modeling of SAP1 and SAP6 with SARS-CoV-2 Spike. The findings from our infectivity assays suggest that SAP1 and SAP6, and to a lesser degree SAP2, block the interaction of SARS-CoV-2 Spike with ACE2. We found that both SAP1 and SAP6 inhibit SARS-CoV-2 infection to similar levels. Since SAP6 contains the minimal conserved short EDLFYQ motif present in SAP1 and SAP2, we conclude that it is the minimal essential motif important for inhibition of SARS-CoV-2. The co-crystal structure of SARS-CoV-2 Spike RBD and human ACE2 has been recently solved and available through the Protein Data Bank (PDB). As shown in Figure 6A, magenta surface and ribbon represent the Spike RBD and yellow ribbon corresponds to ACE2. The RBD-ACE2 interaction interface is contacted mainly by the N-terminal helix (residues Ile21-Asn51) of
ACE2. Our results suggest that SAP6 (Glu37-Gln42, blue ribbon in Figure 6B) and SAP1 (Thr27-Gln42, blue and green ribbon in Figure 6B) are able to disrupt the RBD-ACE2 interaction in low millimolar range, indicating the importance of these residues at the N- terminal helix of ACE2 for RBD-ACE2 interaction. Based on the crystal structure solved by Lan et al. and highlighted in the modeling studies, polar residues (Glu37, Asp38, Tyr41 and Gln42) of SAP6 are able to form a network of hydrogen bonds with Thr500, Tyr449, Asn501, and Tyr505 of SARS-CoV-2 Spike RBD (Figure 6C). In particular, the carboxy groups of Glu37, Asp38, and Gln42 and hydroxyl group of Tyr41 of SAP6 interface with Spike cavity surrounded by Gln498, Thr500, Tyr449, Asn501, and Tyr505. Taken together, these structural insights lend support to our identification of SAP1 and SAP6 as peptide disruptors of the Spike RBD-ACE2 interaction. Evaluation of SAP7. We also evaluated the antiviral potency of SAP7 against lentiviral vectors pseudotyped with SARS-CoV-2 Spike glycoprotein. As described above, luciferase-encoding lentiviruses pseudotyped with SARS-CoV-2 Spike were incubated with increasing concentrations of SAP7 to allow binding to the vector particle-associated Spike prior to infection of HEK293T-ACE2 cells. Luciferase production was then measured 48 hours post-infection. A titration curve for SAP7 was then generated to determining its inhibitory concentration (IC50). The results are shown Figure 7. As shown in Figure 7, SAP7 inhibited SARS-CoV-2 Spike-mediated virus infection with an IC50 value of 0.5 mM. As described above, luciferase-encoding lentiviruses pseudotyped with indicated viral glycoprotein were incubated with 3 mM of SAP7 or diluent control for 1 h prior to infection of 293T-ACE2 cells. Infection was measured as relative luciferase expression 48 h post-infection. The luciferase signal obtained for the diluent control was set to 100%. Graphs indicate percentage of infected cells normalized to the diluent control for lentiviruses pseudotyped with SARS-CoV-2 Spike (Figure 8A), SARS-CoV Spike (Figure 8B), or VSV-G (Figure 8C). In comparison to the diluent control, SAP7 treatment resulted in ~2-fold reduction in SARS-CoV-2 Spike-mediated infection (Figure 8A) and ~4-fold reduction in SARS-CoV Spike-mediated infection (Figure 8B). SAP7 had little (if any) impact on VSV-G-mediated virus infection, consistent with its expected specificity for inhibiting Spike-mediated viral entry (Figure 8C). Conclusion In summary, we have developed and screened a panel of rationally designed, small peptide inhibitors and identified peptides that block the interaction of coronavirus Spike
proteins with ACE2. Importantly, we have identified two peptides, SAP! and SAP6, which inhibit SARS-CoV-2 infection - demonstrating the feasibility of targeting Spike-ACE2 interaction interface with peptide-based inhibitors to inhibit virus infection. SAP6, which contains the minimal conserved EDLFYQ sequence, highlights the importance of the N- terminal al helix of ACE2 for interaction with Spike protein. Future structure-based rational design studies focused on improved conformational matching between SAPs and SARS-CoV-2 Spike protein will allow7 for increased binding affinity and potent viral inhibition. Such approaches could include increased noncovalent interactions between aromatic amino acid residues and the enhancement of peptide a-helicity to increase the stability of the SAPs. Lending support to such approaches, a recent study employed computer-generated scaffolds built around the al helix of ACE2 to design de novo miniprotein inhibitors of SARS-CoV-2. In summary, our proof-of-principle study that SARS-CoV-2 can be inhibited by small peptides will further allow for the successful development of engineered peptides and peptidomimetic-based compounds for the treatment of COVID-19.
Further Investigations and Strategies
Peptide solubility. A major hindrance in commercial application of peptide-based inhibitors is insolubility, poor or low solubility, and/or aggregation of peptides due to long sequences, presence of hydrophobic amino acids, and presence of cysteines. The solubility and aggregation issues are impediments for application of peptide-based inhibitors for therapeutic, prophylactic, and surface virus-inactivation purposes. SAP1-SAP7 were all soluble in IX Phosphate Buffered Saline (PBS). Further, our most active peptide, SAP6 was readily soluble in IX PBS. To improve the solubility of SAP! and SAP2, IX PBS was supplemented with 10% and 5% aqueous NEb, respectively. For SAP! and SAP2, supplementation of IX PBS with 5-10% of aqueous NF Is did not result in any spurious effects when these peptides were tested in various assays at a concentration of 3 mM, which is above the IC50 range for both these peptides. Thus, since solubility of synthetic peptides is often an issue and challenge when working with peptide-based inhibitors, our SAPs are particularly attractive for targeting of SARS-CoV-2 due to their solubility.
Peptide improvement. Even though we are targeting a surface-exposed protein, unmodified peptides can be plagued by poor stability and short plasma half-life when administered by injection to patients. Once positive lead peptides are identified, wze propose to employ a number of structure-based rational design approaches focused on improved
conformational matching between SAPs and SARS-CoV-2 Spike protein, which will allow for increased binding affinity and potent viral inhibition. Such approaches could include increased noncovalent interactions between aromatic amino acid residues and the
enhancement of peptide a-helicity to increase the stability of the SAPs. Our proof-of- principle findings that SARS-CoV-2 can be inhibited by small peptides will allow for the successful development of engineered peptides and peptidomimetic-based compounds for the treatment of COVID-19. Further potential directions are briefly outlined below.
1. Substitutions of amino acid residues in peptides with positive inhibitory profiles, A network of hydrogen bonds with the Spike RBD anchors the most active peptides, SAP1 and SAP6. Because SAP6 contains the minimal conserved short EDLFYQ motif present in SAP1 and SAP2, we conclude that it is useful motif for inhibition of SARS-CoV-2. The polar residues (Glu37, Asp38, Tyrd l and Gln42) of SAP6 are able to form a network of hydrogen bonds with ThrSOO, Tyr449, AsnSOl , and Tyr505 of SARS-CoV-2 Spike RBD. In particular, the carboxy groups of Glu37, Asp38, and Gln42 and hydroxyl group of Tyr41 of SA.P6 interface with Spike cavity surrounded by Gln498, Thr500, Tyr449, Asn501, and Tyr505.
Additionally, Tyr41 of SAP6 provides limited hydrophobic interactions. Thus, we seek to improve the binding affinities and antiviral potencies of our peptides by employing the following approaches: a) In SAP6 there are two surface exposed residues Leu39 and Phe4, which would be normally shielded by other residues in ACE2. Therefore, we will substitute these nonpolar residues with hydrophilic residues such as Lys, Arg, Glu, Asp, Gin, or Asn to increase interactions with solvent water. This should increase its predicated solubility and decrease its overall hydrophobicity. b) Strengthen hydrogen bonding of Glu37, Asp38, and Gln42 with residues that form stronger hydrogen bonds such as His, Tyr or Trp. c) Increase the number of available hydrogen bonds through substitutions of Glu37, Asp38, Tyr41, and Gln42, which can form two hydrogen bonds. Substitutions with Arg, which can form three, and His, which can from four, hydrogen bonds, could pick up additional interactions with the Spike RBD.
d) Increase hydrophobicity of SAP6 through substitutions of Glu37, Asp38, Tyr41, and Gln42 with Trp, which could maintain hydrogen bonding while increasing the hydrophobic nature of the interface residues. e) Extend peptides by three to ten amino acids at the N-terminal and/or C- terminal to determine if the extended peptides improve binding affinity.
2. Generation of a helical hydrocarbon stapled peptides. Our shortest and most active peptide, SAP6, is likely too short to form a stable a helix, which may limit its stability in vivo. Moreover, a formed a helix is more likely to mimic the observed interactions seen in the context of full-length ACE2 protein. As each turn in an a helix contains -3.6 amino acid residues, SAP6 can form approximately a turn and a half. Several different conformations can be achieved for stapling a short six amino acid peptide with a conformation of i, i + 4/, which could stabilize one full helical turn. As an example, S-pentenylalanine can be incorporated into SAP6 to from the peptide staple and help stabilize the a helix. Alternatively, the length of SAP6 can be extended by two to three amino acids in conjunction with incorporation of R- octenylalanine/S-pentenylalanine --- this will allow a conformation of /, i + 7, which could stabilize a double helical turn.
3. Molecular dynamics simulations of peptides. We will use the peptides with positive inhibitory profiles and perform equilibrium molecular dynamics simulation to study the dynamics of Spike RBD-SAP complexes. Such an in silico approach will allow us to measure the end state binding energy calculations, which wall be used to understand the RBD-SAP binding complex at single-residue resolution - amino acid changes that are predicted to increase binding form will then be substituted in the peptides and their binding affinities and antiviral potencies will be evaluated. For promising leads, we will also employ computational alanine scanning to identify amino acid residues that are important for binding of Spike RBD - the identified critical residues will be substituted with other amino acids to enhance binding and antiviral potency.
4. Determination of synergistic and additive effects of peptides. We have developed a panel of peptides and evaluated the antiviral potency against genuine SARS-CoV-2 and HCoV-NL63. The peptides are derived from al , a3, al O, and al l helices of ACE2. Peptides with positive inhibitory profiles would be examined in combination(s) to test for increased potency and/or synergy using our pseudovirus
inhibition assay and SARS-CoV-2 infectivity assays. If synergy or additive effects are observed for given peptides, linkers (such as introduction of giycine(s) or serine(s) resides between peptides) can be engineered to further increase the antiviral potency of Jinked peptides. For example, separate Spike RBD-ACE2 interaction interfaces are targeted by SAPS, SAP4, and SAP6 - SAP3 is derived from a3, SAP4 is derived from al 1 , and SAP6 is derived from al helices of ACE2 and thus predicted to target three distinct interaction of Spike RBD with these regions of ACE2. Thus, evaluating the potencies in combination or through linked peptides would offer two advantages: 1) higher barrier to the evolution of antiviral resistance, and 2) potential increased potency due to synergy and additive effects.
5. Determination of delivery in tissue culture and small animal models of SARS-CoV-2 infection. The short nature of the peptides described herein makes them attractive for use in therapeutic, prophylactic, and surface disinfectant purposes for the following reasons: they likely display enhanced stability in comparison to longer proteins/peptides and the smaller size of these peptides could increase their local molar density with the Spike proteins on virion surface. We would seek to evaluate the prophylactic and therapeutic effectiveness of our most active peptides and derivatives in the rodent/small animal models of SAR.S-CoV-2 infection. We would employ approaches to determine whether delivery of peptides/ derivatives directly in the upper and lower respiratory tracts through intranasal administration, aerosolization, or nebulization would offer protection. We would also evaluate the effectiveness of our most active peptides and derivatives as surface disinfectant by performing virus-inactivation assay, which will be performed by incubation of vims and test peptides/derivate on air-liquid interfaces for increasing amounts of time followed by infection of cells in tissue culture models of SARS-CoV-2 infection.
The compounds, compositions, and methods of the appended claims are not limited in scope by the specific compounds, compositions, and methods described herein, which are intended as illustrations of a few aspects of the claims. Any compounds, compositions, and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the compounds, compositions, and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims. Further, while only certain representative compounds, components, compositions, and method steps disclosed herein are specifically described, other combinations of the
compounds, components, compositions, and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein or less, however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated. The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of” and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments of the invention and are also disclosed. Other than where noted, all numbers expressing geometries, dimensions, and so forth used in the specification and claims are to be understood at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, to be construed in light of the number of significant digits and ordinary rounding approaches. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.
Claims
WHAT IS CLAIMED IS: 1. An isolated peptide comprising the sequence EDX1X2YQ (SEQ ID NO: 20); LX1X2MY (SEQ ID NO: 21), and/or TFX1DKX2X3HE (SEQ ID NO: 22).
2. The isolated peptide of claim 1, wherein the peptide comprises the sequence EDX1X2YQ; wherein X1 is L, A, I, V, G, or P; and wherein X2 is F, Y, or W.
3. The isolated peptide of claim 2, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
4. The isolated peptide of claim 2, wherein the peptide comprises the sequence EDX1X2YQ; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
5. The isolated peptide of claim 1, wherein the peptide comprises the sequence LX1X2MY; wherein X1 is A, I, V, L, G, or P; and wherein X2 is Q, S, T, C, N, or M.
6. The isolated peptide of claim 4, wherein the peptide comprises the sequence LX1X2MY; amd wherein the peptide consists of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.
7. The isolated peptide of claim 4, wherein the peptide comprises the sequence LX1X2MY; amd wherein the peptide does not comprise SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 16, or SEQ ID NO: 17.
8. The isolated peptide of claim 1, wherein the peptide comprises the sequence TFX1DKX2X3HE; wherein X1 is L, A, I, V, G, or P, wherein X2 is F, Y, or W; and wherein X3 is N, Q, S, T, C, or M.
9. The isolated peptide of claim 6, wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
10. The isolated peptide of claim 6, wherein the peptide comprises the sequence TFX1DKX2X3HE; and wherein the peptide does not comprise SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14.
11. A composition comprising one or more of the isolated peptides of any of claims 1- 10.
12. The composition of claim 11, comprising any combination of two or more of the isolated peptides as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, and- SEQ ID NO: 19.
13. The composition of claim 11 or 12, further comprising one or more antiviral agents.
14. The composition of claim 13, wherein the antiviral agent comprises Remdesivir.
15. The composition of claim 13 or 14, wherein the antiviral agent comprises an anti- coronavirus monoclonal antibody, such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or any combination thereof.
16. A method of inhibiting viral entry in a cell of a subject comprising administering to the subject the isolated peptide of claim of any of claims 1-10 or the composition of claims 11-15; wherein the viral entry receptor comprises human angiotensin- converting enzyme 2 (ACE2).
17. A method of inhibiting a viral infection in a subject comprising administering to the subject the isolated peptide of claim of any of claims 1-10 or the composition of claims 11-15.
18. A method of treating a viral infection in a subject comprising administering to the subject the isolated peptide of claim of any of claims 1-10 or the composition of claims 11-15.
19. The method of any of claims 16-18, wherein the virus is a coronavirus.
20. The method of treating a coronaviral infection in a subject of claim 19, wheriein the coronavirus is selected from the group consisting of avian coronavirus (IBV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), feline infectious peritonitis virus (FIPV), feline enteric coronavirus (FECV), canine coronavirus (CCoV), rabbit coronavirus (RaCoV), mouse hepatitis virus (MHV), rat coronavirus (RCoV), sialodacryadenitis virus of rats (SDAV), bovine coronavirus (BCoV), bovine enterovirus (BEV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), porcine hemagglutinating encephalomyelitis virus (HEV), turkey bluecomb coronavirus (TCoV), human coronavirus (HCoV)-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, Severe
Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) (SARS-CoV), Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV)-2 (SARS-CoV-2), or middle east respiratory syndrome (MERS) coronavirus (CoV) (MERS-CoV).
21. The method of claim 20, wherein the SARS-CoV2 virus comprises the B1.351 variant, B.1.1.7 variant, USA-WA1/2020, or P.1 variant.
22. The method of any of claims 16-21 wherein the subject is a human, non-human, primate, cow, horse, pig, chicken, turkey, duck, dog, cat, mouse, rat, rabbit, or guinea pig.
23. The method of any of claims 16, 17, or 19-22, wherein the composition is administered to the subject prior to exposure to or infection with the virus.
24. The method of any of claims 16, 17, or 19-22, wherein the composition is administered to the subject following exposure to or infection with the virus. .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063106689P | 2020-10-28 | 2020-10-28 | |
US63/106,689 | 2020-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022094139A1 true WO2022094139A1 (en) | 2022-05-05 |
Family
ID=81384292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/057132 WO2022094139A1 (en) | 2020-10-28 | 2021-10-28 | Peptide inhibitors for the treatment and prevention of coronavirus infections |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022094139A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11866461B1 (en) | 2023-05-16 | 2024-01-09 | King Faisal University | Fusion peptide inhibitors of human coronavirus 229E |
WO2024096742A1 (en) * | 2022-11-06 | 2024-05-10 | Leyden Laboratories B.V. | SARS-CoV-2 BINDING POLYPEPTIDE |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
US20060257852A1 (en) * | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
US20130330335A1 (en) * | 2010-03-23 | 2013-12-12 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
US20180141998A1 (en) * | 2015-04-23 | 2018-05-24 | Nantomics, Llc | Cancer neoepitopes |
CN112321686A (en) * | 2020-11-16 | 2021-02-05 | 北京大学深圳研究生院 | Stable polypeptide targeting new coronavirus spike protein and application thereof |
US20210324004A1 (en) * | 2020-04-21 | 2021-10-21 | Rush University Medical Center | Peptides for the Treatment of COVID-19 |
-
2021
- 2021-10-28 WO PCT/US2021/057132 patent/WO2022094139A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
US20060257852A1 (en) * | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
US20130330335A1 (en) * | 2010-03-23 | 2013-12-12 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
US20180141998A1 (en) * | 2015-04-23 | 2018-05-24 | Nantomics, Llc | Cancer neoepitopes |
US20210324004A1 (en) * | 2020-04-21 | 2021-10-21 | Rush University Medical Center | Peptides for the Treatment of COVID-19 |
CN112321686A (en) * | 2020-11-16 | 2021-02-05 | 北京大学深圳研究生院 | Stable polypeptide targeting new coronavirus spike protein and application thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024096742A1 (en) * | 2022-11-06 | 2024-05-10 | Leyden Laboratories B.V. | SARS-CoV-2 BINDING POLYPEPTIDE |
US11866461B1 (en) | 2023-05-16 | 2024-01-09 | King Faisal University | Fusion peptide inhibitors of human coronavirus 229E |
US11939354B1 (en) | 2023-05-16 | 2024-03-26 | King Faisal University | Fusion peptide inhibitors of human coronavirus 229E |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schütz et al. | Peptide and peptide-based inhibitors of SARS-CoV-2 entry | |
WO2022094139A1 (en) | Peptide inhibitors for the treatment and prevention of coronavirus infections | |
US10544193B2 (en) | Compositions and methods for treating diseases by inhibiting exosome release | |
CN108472329B (en) | Use of polypeptides to stimulate the immune system | |
US20230348880A1 (en) | Soluble ace2 and fusion protein, and applications thereof | |
EA017957B1 (en) | Influenza inhibiting compositions and methods | |
US9951111B2 (en) | Type I interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis | |
WO2022081827A1 (en) | Chimeric conjugates for degradation of viral and host proteins and methods of use | |
Kathiravan et al. | An overview of spike surface glycoprotein in severe acute respiratory syndrome–coronavirus | |
Gao et al. | Antiviral peptides with in vivo activity: Development and modes of action | |
WO2006128026A2 (en) | Cellular receptor for varicella-zoster virus, methods of inhibiting spread of varicella-zoster and methods of increasing stability and infectivity of the virus | |
US11376306B2 (en) | Peptides and uses therefor as antiviral agents | |
ES2526060T3 (en) | Peptide and treatment for HIV-1 infection | |
JP6910043B2 (en) | Hemagglutinin-binding peptide and preventive / therapeutic agents for influenza virus infections containing it | |
US20240052330A1 (en) | Blockade of sars-cov-2 infection using hydrocarbon stapled peptides | |
Alwan | Al-Akidi Therapeutic Protocol for Severe Infections Associated with Covid-19: Potential and Effective Treatment by Levofloxacin and Vitamin D3 and Zinc (Part 1) | |
KR20060041163A (en) | Antiviral agents for the treatment, control and prevention of infections by coronaviruses | |
WO2022036049A2 (en) | Antiviral stapled peptides against sars-cov-2 | |
CN116782920A (en) | Neuropilin and angiotensin converting enzyme 2 fusion peptides for the treatment of viral infections | |
US11548919B1 (en) | SARS-CoV-2 polypeptide inhibitors directed against the Env TM domain and methods of treatment using said inhibitors | |
NL2027924B1 (en) | Antimicrobial peptide for prevention and treatment of virusinfections | |
US20230355708A1 (en) | Compositions for inhibiting viral entry and methods using same | |
US20230235301A1 (en) | Compounds and Methods for Treating, Ameliorating, or Preventing Herpes Ocular Keratitis | |
EP4269424A1 (en) | Novel antiviral compounds and use thereof | |
KR20240095267A (en) | Modified tripeptides for use in the treatment of non-enveloped viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21887560 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21887560 Country of ref document: EP Kind code of ref document: A1 |